Multibranched glycolipid mimetics

JP2024542024AInactive Publication Date: 2024-11-13CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525641
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-29
Filing Date
2022-10-24
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2024542024000001_ABST
    Figure 2024542024000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound of formula I, wherein X, Y, Z and R 1 The present invention relates to a multi-branched glycolipid mimetic of formula I, or a pharmaceutical composition thereof, and to the use thereof as a medicament, in particular for the treatment and / or prevention of immune diseases caused by a Th1 / Th2 imbalance. The present invention further relates to a vaccine comprising a compound of formula I. [Formula 1] JPEG2024542024000038.jpg30169
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] The present invention relates to a polybranched glycolipid mimetic of formula I or a pharmaceutical composition thereof, and to its use as a medicament, in particular for the treatment and / or prevention of immune diseases caused by a Th1 / Th2 imbalance. The present invention further relates to a vaccine comprising the compound of formula I. [Background technology] Carbohydrates play a key role in regulating immune system function and immune responses. It is not surprising that a variety of natural carbohydrate-based immunomodulators have been clinically evaluated, ranging from cancer immunotherapy or vaccine adjuvants to the treatment of autoimmune or infectious diseases. However, immune active carbohydrates derived from nature are usually difficult to obtain in sufficient quantities, purity and homogeneity. Organic synthetic chemistry, including total synthesis and semi-synthetic strategies, allows for corresponding structural modifications of natural products with a high level of chemical control, providing a more attractive approach to molecularly defined improved versions of carbohydrate-containing immune stimulants, carbohydrate-containing immunoactivators or immunosuppressants. The importance of carbohydrate derivatives, especially glycolipids, as immunomodulatory agents is shown in the following reviews: Molecules 2013, 18, 15662-15688; Clinical & Translational Immunology 2016, 5, e69; Chemistry A European Journal 2017, 23, 1728-1742; Nature Reviews Chemistry 2021, doi: doi.org / 10.1038 / s41570-020-00244-3. Among synthetic glycomodulators, glycolipids with agonistic or antagonistic activity against human invariant natural killer T cells (iNKT cells) are one family of candidates expected to be developed clinically. Natural killer T cells (NKT cells) were traditionally defined as T cells that constitutively express NK-associated receptors in naive mice. Subsequent classification of subsets with these common properties defined a major population known as type 1 or invariant NKT cells (iNKT cells). These cells express an invariant TCR α chain (Vα14Jα18 in mice and Vα24Jα18 in humans) paired with a TCR β chain with limited diversity. iNKT cells recognize lipids and glycolipids presented by CD1d, a conserved nonpolymorphic MHC class I-like molecule, and recognize a variety of synthetic glycosylceramides as well as natural self- or microbial glycolipids.

[0002] An exemplary synthetic iNKT cell antibody is a synthetic α-galactosylceramide (αGalCer) known as KRN7000. αGalCer is a saturating C 26 C linked with N-acyl chain 18 It contains phytosphingosine. αGalCer has been extensively studied as a model antigen for C18iNKT cells in humans as well as other animal models including mice, rats and primates. iNKT cells exert multiple immunoregulatory functions when stimulated with KRN7000, aided by a broad and rapid secretion of cytokines. iNKT cells have a remarkable ability to simultaneously produce cytokines classically associated with both T helper 1 (Th1) responses (e.g., IFNγ, TNFα) and T helper 2 (Th2) responses (IL-4, IL-5, IL-13). Furthermore, their activation leads to induction of dendritic cell (DC) maturation, transcriptional promotion of NK cells and help to B cells. KRN7000-stimulated iNKT cells have shown the ability to modulate or improve immune responses depending on disease models, including tumors, microbial diseases, allergic diseases and autoimmune diseases.

[0003] Although αGalCer is a standard model for iNKT cell antigens, it has limitations that hinder its therapeutic efficacy. The first major problem is that KRN7000 tends to induce high levels of both Th1 and Th2-related cytokines. These cytokines may have direct opposing activities that lead to ineffective and unexpected immune responses. In addition, αGalCer may stimulate iNKT cells too strongly, resulting in a cytokine storm; that is, iNKT cells release large amounts of cytokines, leading to anergy or inactivation of iNKT cells. Due to the therapeutic potential of iNKT cells and the limitations of αGalCer, there have been intensive efforts to identify structural analogs with the ability to selectively stimulate a limited range of iNKT cell functions. The following selected reviews provide an overview of this topic: Cell Chemical Biology 2018, 25, 571-584; Organic & Biomolecular Chemistry 2011, 9, 3080-3104. The following patent documents are a collection of specific examples regarding the synthesis and application of αGalCer analogues as immunomodulatory agents: US5,936,076; US7928,077B2; WO2007 / 050668A1; US8,580,751B2; US2011 / 0028411A1; US8,883,746B2; WO2019 / 102054A1; US2008 / 0260774A1; US2015 / 0071960A1; US2010 / 0035843A1.

[0004] From the series of studies reported in the above cited references, it can be deduced that the structure of the designed αGalCer-inspired glycolipid antigen for iNKT cells can be theoretically divided into four parts: lipid chain, sphingosine / ceramide head group, glycosidic linkage, and sugar nature. All four have been chemically modified to improve the candidate immunomodulatory glycolipids. In particular, the focus has been on obtaining glycolipids that stimulate purely Th1 or Th2 cytokine-biased iNKT cell responses.

[0005] Multiple classes of αGalCer mutants effectively induce Th1 responses from iNKT cells. These responses have proven to be effective in vaccine adjuvants and in the treatment of several forms of cancer. Early modifications of the sugar moiety showed that the pyranose shape, especially the α-anomeric structure, is essential for adjuvant activity. Substitution or addition of the 6''-OH group (the primary OH group of the galactopyranosyl moiety) by, for example, amides, carbamates, or ureas promotes Th1-biased immune responses. The Th1-biased immune response is due to increased stability in vivo, which favors IFNγ expression over IL4 expression in the long term. The more stable α-carba-GalCer mutants, in which the endocyclic oxygen is replaced by a carbon, are immunostimulatory glycolipids with strong Th1 inducibility. Similarly, replacement of the exocyclic glycosidic oxygen with a methylene unit yielded the corresponding C-glycoside analog (α-C-GalCer) that exhibited a pronounced Th1 response in mice. However, studies using cell culture models of human iNKT cell responses have shown that α-C-GalCer only exhibits weak stimulatory properties, suggesting that it may not be suitable for development as a human therapeutic. A thioglycoside analog, α-S-GalCer, was also synthesized, but it showed no bioactivity in mice and induced a Th1 profile in humans. In contrast, a KRN7000 analog in which the ring oxygen of the galactopyranose residue was replaced by a nitrogen atom in addition to mutation of the ceramide moiety was reported in the literature Chinese Journal of Chemistry 2017, 35, 1001-1008 to have no activity in inducing cytokine release.

[0006] Another potent Th1-biased iNKT cell agonist previously identified is an aminodiol (sphinganine) analog of KRN7000 called AH03-1. AH03-1 lacks the OH group at the 4' position of the sphingosine lipid chain. AH03-1 and other related sphinganine analogs have generally been found to be highly active in vivo in mice. However, they were not efficient activators in cell culture models of human iNKT cell responses. A variety of other αGalCer analogs with diverse structural modifications in the lipid moiety have also been synthesized, allowing further structure-activity relationship (SAR) studies. The following paper further illustrates the current state of the technology: PLoS ONE 2010, 5, e14374.

[0007] Few α-GalCer-related antigens have been discovered that induce Th2 immunomodulatory responses. Activation of iNKT cells by this type of antigen is generally considered to be useful in reducing inflammation and ameliorating autoimmune diseases. Such compounds include C20:2αGalCer (with unsaturated acyl chains) and OCH (with truncated sphingosine chains). αGalCer analogs modified at the 6'' position of the glycan, such as 6''-triazole-substituted derivatives and 6-O-alkylated derivatives with long ether-linked fatty chains, also induced a moderate Th2 profile.

[0008] iNKT cells have also been associated with disruption of mucosal homeostasis in the intestine and airways, and contribute to allergic airway inflammation in various allergen models, including ovalbumin (OVA) and house dust mite (HDM) extract, through Th2-biased cytokine responses. Indeed, iNKT cells have been found to be necessary for the development of airway hyperresponsiveness (AHR). Compositions that reduce CD1d-restricted iNKT cell responses can be used to treat allergen-induced airway hyperresponsiveness associated with CD1d-restricted iNKT cell activation, such as asthma and allergic rhinitis. In addition, iNKT cells also contribute to acute immune-mediated hepatitis by inducing liver injury. Prior art has shown that the pathology of iNKT cell-induced liver disease can be reduced by inhibiting iNKT cell activation using glycolipid antagonists. Examples of α-GalCer analogs with iNKT antagonist behavior that have the potential to treat iNKT cell-mediated diseases include α-mannopranosylceramide (α-ManCer) and α-lactosylceramide (α-LacCer), reported in the non-patent literature Frontiers in Chemistry 2019, 7, 811.

[0009] Among the reported α-GalCer analogs with immunomodulatory activity, glycosylserine-type hyperbranched glycolipids, exemplified by a compound called CCL-34, are a unique class. CCL-34 is a glycosylserine-type glycosphingolipid in which the galactopyranosyl moiety is α-linked to the hydrophobic lipid moiety of a serine group and linear N-linked C-glycosyl groups are attached to the carbonyl groups of amino acids. 11 Contains lipid chains, forms amide bonds, and has linear C 12 There is an acyl substituent. CCL-34, but not a-GalCer itself, was found to be a Toll-like receptor 4 (TLR4) agonist. The potential of CCL-34 glycolipid as an immunomodulatory substance is shown in the following report: Scientific Reports, 2020, 10, 8422. Toll-like receptor 4 (TLR4) is a mammalian receptor that recognizes endotoxins (lipopolysaccharide, LPS, or lipooligosaccharide, LOS) from Gram-negative bacteria. TLR4 is expressed primarily on the cell surface of epithelial cells and innate immune cells, where it senses minute amounts of LPS released by Gram-negative bacteria. A series of sequential interactions between the lipophilic portion of LPS and the LBP3, CD14, and MD-2 coreceptors results in the formation of an activated membrane heterodimer complex (LPS / MD-2 / TLR4) 2 This allows the formation of TLR4-mediated cytokines, which induce intracellular signals that induce the production of inflammatory cytokines and chemokines. Although TLR4-mediated cytokine production is an essential mechanism for the host organism to respond to infection, excessive stimulation of TLR4 by pathogen-associated molecular patterns (PAMPs) can cause uncontrolled cytokine production, leading to severe and life-threatening syndromes such as acute sepsis and septic shock. Activation of TLR4 by endogenous factors (DAMPs) is associated with several inflammatory and autoimmune diseases that affect various organs and bodily functions. In this context, there is growing interest in developing hit or lead compounds that can modulate TLR4 signaling for a wide range of potential therapeutic environments, which can be inferred from the following reports:Scientific Reports, 2019, 9, 919; Organic & Biomolecular Chemistry 2011, 9, 2492-2504; Biochemical Pharmacology 2007, 73, 1957-1970.

[0010] As can be inferred from the above paragraphs and the cited patent and non-patent literature, there are several examples of immunomodulatory glycolipids that regulate the balance of Th1 / Th2 cells. Almost all glycolipids contain mono-, di- or oligosaccharide moieties as glycocones (the sugar moieties of glycolipids), and their synthesis involves the formation of a glycosidic bond between a glycosyl donor and a lipid precursor acceptor as a key step. This generally means that both α and β isomers can be formed, necessitating laborious separation. Furthermore, glycocon sugars and glycosidic bonds can be chemically and metabolically unstable. Finally, the Th1 / Th2 regulatory activity is often suboptimal.

[0011] In view of the above, it may be useful to identify further glycolipid-like agents that can directly and specifically induce or modulate immune responses by either agonizing or antagonizing iNKT cells or TLR4 receptors. Of particular note is the development of new strategies that allow such compounds to be utilized with high efficiency, while ensuring: (a) perfect α-stereoselectivity in generating the glycosidic bond, (b) metabolic stability, and (c) compatibility with molecular diversity-oriented strategies, thus allowing systematic modification of the structure to optimize the immunomodulatory profile.

[0012] Summary of the Invention A first aspect of the present invention relates to a compound of formula I: [ka] where R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 12 Alkyl, C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 has been replaced by; R2 -OH, -N(R 3 ) 2 , -N 3 , C 1 -C 14 is alkyl or halogen; R 3 are each independently H or C 1 -C 4 is alkyl; X is O, S, NH or CH 2 and; Y is the group NH-C(=O)-Y', the group NH-C(=O)-NHY', the group NH-C(=S)-NHY', the group NH-SO 2 -Y', or a group of formula Ia: [ka] Y' is one or more groups R 4 , preferably one or two groups R 4 , more preferably one group R 4 C optionally substituted with 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and; Cy 1 is a 5- to 14-membered ring which may be saturated, partially unsaturated or aromatic and optionally contains a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P; Cy 1 is optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring, which may be saturated, partially unsaturated, or aromatic; Cy 1 is optionally phenyl, halogen, C1 -C 4 Alkyl, halo-C 1 -C 4 Alkyl, -OC 1 -C 4 Alkyl, -OCOO-C 1 -C 4 Alkyl, -CO-C 1 -C 4 Alkyl, SC 1 -C 4 Alkyl or N 3 -C 1 -C 4 substituted with one or more groups selected from alkyl; Z is -CO-OC 4 -C 25 Alkyl, -CO-NH-C 4 -C 25 Alkyl or C 4 -C 25 alkyl, where Z is optionally selected from one or more groups R 5 and preferably Z is -CO-OC 4 -C 25 Straight chain alkyl, -CO-NH-C 4 -C 25 Linear alkyl or C 4 -C 25 is a linear alkyl group, where Z is optionally selected from one or more groups R 5 is replaced by; and R 5 are each independently -OH, -OCH 2 Ph(-OBn), -OC(=O)Ph(-OBz), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 It is.

[0013] In another embodiment, the present invention provides a method for the preparation of 1are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, wherein R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently optionally selected from -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 is selected from alkyl.

[0014] In another embodiment, the present invention provides a method for the preparation of 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; R 1 each independently optionally represents one or more groups R 2 It relates to compounds of formula I as defined above, which are substituted by:

[0015] In another embodiment, the present invention relates to compounds of formula I as defined above, wherein R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 is selected from alkyl.

[0016] In another embodiment, the invention relates to compounds of formula I as defined above, wherein X is O or S.

[0017] In another embodiment, the present invention relates to compounds of formula I as defined above, wherein Y is a group NH-C(=O)-Y', a group NH-C(=S)-NHY', a group NH-SO 2 -Y', or a group of formula Ia.

[0018] In another embodiment, the present invention relates to compounds of formula I as defined above, wherein: Y is a group NH-C(=O)-Y', a group NH-C(=S)-NHY', a group NH-SO 2 - Y'; Y' optionally comprises one or more groups R 4 , preferably one or two groups R 4 , more preferably one group R 4 C replaced by 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and preferably R 4 -OH, OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 , more preferably R 4 Cy 1 and more preferably R4 is Ph.

[0019] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein: Y is a group of formula Ia; and Y' optionally comprises one or more groups R 4 C replaced by 1 -C 25 alkyl, preferably Y′ is optionally selected from one or more groups R 4 C replaced by 1 -C 12 It is an alkyl.

[0020] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein: Y is a group of formula Ia; Y' is C 1 -C 25 alkyl, preferably Y' is C 1 -C 12 It is an alkyl.

[0021] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein: Y is a group of formula Ia; and Y' optionally comprises one or more groups R 4 C replaced with 1 -C 25 A straight chain alkyl, preferably Y′ is C 1 -C 25 More preferably, Y' is C 1 -C 12 It is a straight chain alkyl.

[0022] In another embodiment, the present invention relates to compounds of formula I as defined above, wherein Z optionally represents one or more groups R 5 Substituted by -CO-NH-C 4 -C 25 alkyl; preferably, Z is -CO-NH-C 8 -C 20 alkyl, optionally with one or more groups R5 and more preferably Z is substituted by -CO-NH-C 14 -C 16 alkyl, optionally with one or more groups R 5 and more preferably Z is substituted by -CO-NH-C 4 -C 25 More preferably, Z is -CO-NH-C 8 -C 20 It is a straight chain alkyl.

[0023] In another embodiment, the present invention relates to compounds of formula I as defined above, wherein: Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is replaced by; and R 5 are each independently -OH or -OC(=O)Ph(-OBz).

[0024] In another embodiment, the present invention relates to a compound of formula I as defined above, wherein: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl; X is O or S; Y is the group NH-C(=O)-Y', the group NH-C(=S)-NHY', the group NH-SO 2 -Y', or a group of formula Ia; Z is -CO-NH-C 4 -C 25 and preferably Z is -CO-NH-C 8 -C 20 It is a straight chain alkyl.

[0025] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl; X is O or S; Y is the group NH-C(=O)-Y', the group NH-C(=S)-NHY', the group NH-SO 2 -Y', or a group of formula Ia; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is replaced by; and R 5 are each independently -OH or -OC(=O)Ph(-OBz).

[0026] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; X is O or S; Y is the group NH-C(=O)-Y', the group NH-C(=S)-NHY', the group NH-SO 2 -Y', or a group of formula Ia; Z is -CO-NH-C 4 -C 25 alkyl and one or more groups R 5 Preferably Z is -CO-NH-C 4 -C 20 alkyl, optionally with one or more groups R 5 is replaced by

[0027] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; X is O or S; Y is the group NH-C(=O)-Y', the group NH-C(=S)-NHY', the group NH-SO 2 -Y', or a group of formula Ia; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 Replaced with; R 5 are each independently -OH or -OC(=O)Ph(-OBz).

[0028] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl; X is O or S; Y is a group NH-C(=O)-Y', a group NH-C(=S)-NHY', a group NH-SO 2 - Y'; Y' is optionally one or more groups R 4 C replaced with 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and preferably R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 , more preferably R 4 Cy 1 and more preferably R 4 is Ph; Z is -CO-NH-C 4 -C 25 alkyl, optionally with one or more groups R 5 and preferably Z is -CO-NH-C 4 -C 20 alkyl and one or more groups R 5 is optionally replaced by

[0029] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 14 alkyl; X is O or S; Y is a group NH-C(=O)-Y', a group NH-C(=O)-NHY', a group NH-C(=S)-NHY' or a group NH-SO 2 - Y'; Y' optionally comprises one or more groups R 4 C replaced with 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and preferably R 4 -OH, OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and more preferably R 4 Cy 1 and more preferably R 4 is Ph; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is substituted with; and R 5 are each independently -OH or -OC(=O)Ph(-OBz).

[0030] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 and X is O or S, preferably R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; X is O or S; Y is a group NH-C(=O)-Y', a group NH-C(=S)-NHY', a group NH-SO 2 - Y'; Y' is one or more groups R 4 C optionally substituted with 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and preferably R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 , more preferably R 4 Cy 1 and more preferably R 4 is Ph; Z is -CO-NH-C 4 -C 25 and preferably Z is -CO-NH-C 4 -C 20 It is a straight chain alkyl.

[0031] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 and X is O or S, preferably R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; Y is a group NH-C(=O)-Y' or a group of formula Ia; Y' optionally comprises one or more groups R 4C replaced with 1 -C 25 is alkyl; R 4 -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and preferably R 4 -OH, OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, -OC 1 -C 12 Alkyl, -SC 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and more preferably R 4 Cy 1 and more preferably R 4 is Ph; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is substituted with; and R 5 are each independently -OH or -OC(=O)Ph(-OBz).

[0032] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently represents one or more groups R 2 and optionally substituted by R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl; X is O or S; Y is a group of formula Ia; Y' optionally comprises one or more groups R 4 C replaced with 1 -C 25 alkyl, preferably Y' is C 1 -C 25 More preferably, Y' is C 1 -C 12 is a straight chain alkyl; Z is -CO-NH-C 4 -C 25 alkyl, optionally with one or more groups R 5 and preferably Z is -CO-NH-C 8 -C 20 alkyl, optionally with one or more groups R 5 is replaced by

[0033] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 4 Alkyl, C 1 -C 4 alkyl, where R 1each independently optionally represents one or more groups R 2 and preferably R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl, where R 1 each independently optionally represents one or more groups R 2 More preferably, R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-CH 3 , C 1 -C 4 alkyl; X is O or S; Y is a group of formula Ia; Y' optionally comprises one or more groups R 4 C replaced with 1 -C 25 alkyl, preferably Y′ is optionally selected from one or more groups R 4 C replaced with 1 -C 25 More preferably, Y′ is C 1 -C 12 is a straight chain alkyl; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is substituted with; and R 5 are each independently -OH or -OCH 2 Ph(-OBn).

[0034] In another embodiment, the present invention relates to a compound of formula I as defined above: R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl, where R 1each independently optionally represents one or more groups R 2 and X is O or S, preferably R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; Y is a group of formula Ia; Y' optionally comprises one or more groups R 4 C replaced with 1 -C 25 alkyl, preferably Y′ is optionally selected from one or more groups R 4 C replaced with 1 -C 25 More preferably, Y′ is C 1 -C 12 is a straight chain alkyl; Z is C 4 -C 25 alkyl, where Z is a group consisting of two groups R 5 is substituted with; and R 5 are each independently -OH or -OCH 2 Ph(-OBz).

[0035] In another embodiment, the compound of formula I as defined above is selected from: [Table 1] JPEG2024542024000005.jpg221169 JPEG2024542024000006.jpg221169 JPEG2024542024000007.jpg227169 JPEG2024542024000008.jpg124169 In some embodiments, any stereochemical pattern of polysubstituted 2-oxa-3-oxoindolizin-5-yl, any structure of CH groups with Y and Z substituents, and any substituent R in compounds 1-31 are also usable. 1Any of X, Y and / or Z may be independently combined, i.e., the individual substituents may be selected from multiple compounds as if each specific combination was explicitly recited.

[0036] As used herein, the singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. For example, "a compound" refers to one or more of such compounds known to those of skill in the art.

[0037] Throughout this application, the term "compound" or "compounds" refers to the compounds discussed herein and is intended to include precursors and derivatives of the compounds, including acyl-protected derivatives, as well as pharma- ceutically acceptable salts of the compounds, precursors and derivatives.

[0038] In another embodiment, the compound of the present disclosure can act as an agonist or antagonist of iNKT cells, or as an agonist or antagonist of TLR-4 receptor in immune system cells.In yet another embodiment, the compound of the present disclosure can induce Th1 type, Th2 type, or Th1 type and Th2 type response.In another embodiment, the compound of the present invention can counteract the Th1 type, Th2 type, or Th1 type and Th2 type response caused by a third agent.In an exemplary embodiment, the compound of the present invention can act in vitro as an agonist or antagonist of iNKT cells, or as an agonist or antagonist of TLR-4 receptor in immune system cells.In another embodiment, the compound of the present invention can act in vitro as an agonist or antagonist of iNKT cells, or as an agonist or antagonist of TLR-4 receptor in immune system cells.

[0039] The present invention also includes prodrugs of the compounds, pharmaceutical compositions comprising the compounds and a pharma- ceutically acceptable carrier, and pharmaceutical compositions comprising prodrugs of the compounds and a pharma- ceutically acceptable carrier.

[0040] The compounds of formula I of the present invention may contain one or more asymmetric centers, and therefore may exist as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may exist depending on the nature of the various substituents on the molecule. Each such asymmetric center independently produces two optical isomers, and it is intended that all possible optical isomers and diastereomers, both as mixtures and pure or partially purified compounds, are included within the scope of the present invention. Any formula, structure or name of a compound described herein that does not specify a specific stereochemistry is intended to include any existing isomers as described above, and mixtures thereof in any proportion. When a stereochemistry is specified, the present invention is meant to include that specific isomer in pure form or as part of a mixture with other isomers in any proportion.

[0041] Thus, the compounds of formula I of the present invention may contain chiral centers or double bonds. When they contain chiral centers, they may ambiguously have the (R) or (S) configuration. When they contain double bonds, they may ambiguously have the (Z) or (E) configuration.

[0042] As used herein, the term "hyperbranched lipid" refers to a lipophilic moiety that contains two or more hydrocarbon or substituted hydrocarbon tails.

[0043] The term “C 1 -C 4 Alkyl, C 1 -C 12 Alkyl, C 1 -C 25 Alkyl, C 8 -C 20 Alkyl, C 4 -C 25"Alkyl" and the like, as a group or part of a group, means a straight or branched alkyl chain containing, respectively, 1 to 4, 1 to 12, 1 to 25, 8 to 20, or 4 to 25 carbon atoms.

[0044] "C 1 -C 25 Straight chain alkyl" or "-CO-NH-C 4 -C 25 The term "straight chain alkyl" as part of a group such as "straight chain alkyl" means a straight chain alkyl as defined above.

[0045] "Halogen" means fluoro, chloro, bromo or iodo.

[0046] Terminology Cy 1 refers to a 5- to 14-membered ring that may be saturated, partially unsaturated, or aromatic, optionally containing a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P; Cy 1 can be optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring, which may be saturated, partially unsaturated, or aromatic; Cy 1 is optionally phenyl, halogen, C 1 -C 4 Alkyl, halo-C 1 -C 4 Alkyl, -OC 1 -C 4 Alkyl, -OCOO-C 1 -C 4 Alkyl, -CO-C 1 -C 4 Alkyl, SC 1 -C 4 Alkyl, or N 3 -C 1 -C 4For example, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, azolidine, oxolane, thiolane, phophorane, piperidine, piperazine, tetrahydropyran, oxane, 1,4-dioxane, morpholine, phosphinane, phenyl, biphenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4-benzodioxanyl, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1, These include 2,3-oxadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, imidazole, benzimidazole, benzoxazole, benzothiazole, indolizine, indole, isoindole, benzofuran, benzothiophene, 1H-indazole, purine, 4H quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.

[0047] In the definition of cyclic groups used throughout this specification, for example, Cy 1 Unless a restriction is indicated and applies, such as the ring being bonded via a C atom in the corresponding definition of the cyclic group, when the cyclic group is referred to in general terms as a ring radical, such as pyridyl, thienyl, or indolyl, all available bonding positions are included.

[0048] For example, "optionally substituted" means that the referenced group can be substituted or unsubstituted, that both substituted and unsubstituted groups are included in the description, and that substitution can occur one or more times.

[0049] The phrase "optionally substituted with one or more" means that the group can be substituted with one or more, preferably 1, 2, 3 or 4 substituents, more preferably 1, 2 or 3 substituents, and even more preferably 1 or 2 substituents. The substituents can be the same or different and can be located at any available position.

[0050] The compounds of the present invention can be prepared by various known methods, in which a suitable polysubstituted 2-oxa-3-oxoindolizidine derivative having a reactive group at C-5 position is reacted with a suitable precursor of the lipid moiety to form a glycoside-like bond. This reaction is called the coupling step. For example, the compounds of formula I can be obtained by coupling a polysubstituted 2-oxa-3-oxoindolizidine with a lipid precursor according to the following scheme 1 or a method similar thereto. [ka] where in Scheme 1, L is a leaving group, and the structural pattern of the glycocon and lipid moieties A and B is represented by I and R 1is defined as above for I, and Y and Z are defined as above for I, except that any functional groups that may interfere with step 1 are sufficiently protected to avoid side reactions. For example, but not limited to, hydroxyl groups can be protected as ester or ether derivatives, amino groups can be protected as amide or carbamate derivatives, and thiol groups can be protected as thioester or thioether derivatives. Examples of esters are acetyl and benzoyl derivatives. Examples of ethers are benzyl or p-methoxybenzyl derivatives. Examples of amides are trifluoroacetamide derivatives. Examples of carbamates are tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenyloxycarbonyl (Fmoc) derivatives. Examples of thioester derivatives are S-acetyl derivatives. Examples of thioether derivatives are Sp-methoxybenzyl or S-2,4,6-trimethoxybenzyl thioether derivatives. The protecting groups are optional and can be fully or partially removed in a subsequent step.

[0051] Examples of leaving groups L include hydroxyl, acyloxy (e.g., acetoxy), trichloroacetamidoyloxy, and phosphate esters [-OP(=O)(OPh) 2 etc.], halogens (Br, F, etc.), etc.

[0052] In some embodiments, the glycolipid mimic obtained after the coupling step as described above is then subjected to further transformations to finally obtain a polybranched glycolipid mimic. For example, compounds of formula I, such as compounds 11, 12, 30 or 31, having a structural profile similar to that of α-D-glucopyranoside, represented by general formula (II), where X is O and Y is NHC(=O)Y', and compounds of formula I, such as compounds 13 or 14, having a structural profile similar to that of α-D-glucopyranoside, represented by general formula (III), where X is O and Y is NHC(=S)NHY', can be obtained according to the following scheme 2 or a method similar thereto; compounds of formula I, such as compounds 15-24, having a structural profile similar to that of α-D-glucopyranoside, represented by general formula (IV), where X is S and Y is NHC(=O)Y', and compounds of formula I, such as compounds 16-28, having a structural profile similar to that of α-D-glucopyranoside, represented by general formula (V), where X is S and Y is NHSO 2 Compounds of formula I, such as compounds 24 or 25, having a structural profile similar to that of α-D-glucopyranosides, where X is O and Y is NHC(=O)Y', can be obtained according to the following scheme 3 or a method similar thereto; compounds of formula I, such as compounds 26 or 27, having a structural profile similar to that of α-D-galactopyranoside, where X is O and Y is NHC(=O)Y', can be obtained according to the following scheme 4 or a method similar thereto; and compounds of formula I, such as compounds 28 or 29, having a structural profile similar to that of α-D-galactopyranoside, where X is S and Y is NHC(=O)Y', can be obtained according to the following scheme 5 or a method similar thereto. [ka] where L is a leaving group, the structural patterns of the B' and B'' lipid moieties in the lipid precursor and glycolipid-mimetic intermediate are identical to the structural pattern of B in compounds (II) and (III), and R 1and Y' is defined as above for I, and Z is -CO-NH-C 4 -C 25 alkyl, and optionally one or more groups R 5 However, any functional groups that may interfere with the reaction in steps 1, 2 or 3 are sufficiently protected to avoid side reactions. For example, but not limited to, hydroxyl groups can be protected as ester or ether derivatives, amino groups can be protected as amide or carbamate derivatives, and thiol groups can be protected as thioester or thioether derivatives. Examples of esters are acetyl and benzoyl derivatives. Examples of ethers are benzyl or p-methoxybenzyl derivatives. Examples of amides are trifluoroacetamide derivatives. Examples of carbamates are tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenyloxycarbonyl (Fmoc) derivatives. Examples of thioester derivatives are S-acetyl derivatives. Examples of thioether derivatives are Sp-methoxybenzyl or S-2,4,6-trimethoxybenzyl thioether derivatives. The protecting groups are optional and can be removed in whole or in part in a later step.

[0053] Examples of leaving groups L include hydroxyl, acyloxy (e.g., acetoxy), trichloroacetamidoyloxy, and phosphate esters [-OP(=O)(OPh) 2 etc.], halogens (Br, F, etc.), etc. [ka] where L is a leaving group, the structural patterns of the B' and B'' lipid moieties in the lipid precursor and glycolipid-mimetic intermediate are identical to the structural pattern of B in compounds (IV) and (V), and R 1 and Y' is defined as above for I, and Z is -CO-NH-C 4 -C 25 alkyl, and optionally one or more groups R 5However, functional groups that may interfere in steps 1, 2 or 3 are sufficiently protected to avoid side reactions. For example, but not limited to, hydroxyl groups can be protected as ester or ether derivatives, amino groups can be protected as amide or carbamate derivatives, and thiol groups can be protected as thioester or thioether derivatives. Examples of esters are acetyl and benzoyl derivatives. Examples of ethers are benzyl or p-methoxybenzyl derivatives. Examples of amides are trifluoroacetamide derivatives. Examples of carbamates are tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenyloxycarbonyl (Fmoc) derivatives. Examples of thioester derivatives are S-acetyl derivatives. Examples of thioether derivatives are Sp-methoxybenzyl or S-2,4,6-trimethoxybenzyl thioether derivatives. The protecting groups are optional and can be removed in whole or in part in a later step.

[0054] Examples of leaving groups L include hydroxyl, acyloxy (e.g., acetoxy), trichloroacetamidoyloxy, and phosphate esters [-OP(=O)(OPh) 2 etc.], halogens (Br, F, etc.), etc. [ka] where L is a leaving group, the structural patterns of the B' and B'' lipid moieties in the lipid precursor and glycolipid-mimetic intermediate are identical to the structural pattern of B in compound (VI), and R 1 and Y' is defined as above for I, and Z is -CO-NH-C 4 -C 25 alkyl, and optionally one or more groups R 5However, any functional groups that may interfere with the reaction in steps 1, 2 or 3 are sufficiently protected to avoid side reactions. For example, but not limited to, hydroxyl groups can be protected as ester or ether derivatives, amino groups can be protected as amide or carbamate derivatives, and thiol groups can be protected as thioester or thioether derivatives. Examples of esters are acetyl and benzoyl derivatives. Examples of ethers are benzyl or p-methoxybenzyl derivatives. Examples of amides are trifluoroacetamide derivatives. Examples of carbamates are tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenyloxycarbonyl (Fmoc) derivatives. Examples of thioester derivatives are S-acetyl derivatives. Examples of thioether derivatives are Sp-methoxybenzyl or S-2,4,6-trimethoxybenzyl thioether derivatives. The protecting groups are optional and can be removed in whole or in part in a later step.

[0055] Examples of leaving groups L include hydroxyl, acyloxy (e.g., acetoxy), trichloroacetamidoyloxy, and phosphate esters [-OP(=O)(OPh) 2 etc.], halogens (Br, F, etc.), etc. [ka] where L is a leaving group, the structural patterns of the B' and B'' lipid moieties in the lipid precursor and glycolipid-mimetic intermediate are identical to the structural pattern of B in compound (VII), and R 1 and Y' is defined as above for I, and Z is -CO-NH-C 4 -C 25 alkyl, and optionally one or more groups R 5However, any functional groups that may interfere with the reaction in steps 1, 2 or 3 are sufficiently protected to avoid side reactions. For example, but not limited to, hydroxyl groups can be protected as ester or ether derivatives, amino groups can be protected as amide or carbamate derivatives, and thiol groups can be protected as thioester or thioether derivatives. Examples of esters are acetyl and benzoyl derivatives. Examples of ethers are benzyl or p-methoxybenzyl derivatives. Examples of amides are trifluoroacetamide derivatives. Examples of carbamates are tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenyloxycarbonyl (Fmoc) derivatives. Examples of thioester derivatives are S-acetyl derivatives. Examples of thioether derivatives are Sp-methoxybenzyl or S-2,4,6-trimethoxybenzyl thioether derivatives. The protecting groups are optional and can be removed in whole or in part in a later step.

[0056] Examples of leaving groups L include hydroxyl, acyloxy (e.g., acetoxy), trichloroacetamidoyloxy, and phosphate esters [-OP(=O)(OPh) 2 etc.], halogens (F, Cl, Br or I), etc.

[0057] Another aspect of the present invention relates to a pharmaceutical composition comprising at least one compound of formula I or any mixture or combination thereof. The compositions of the present invention optionally comprise at least one of a pharma- ceutically acceptable carrier, diluent, excipient and / or additive.

[0058] Another aspect of the invention relates to a compound of formula I as defined above or a pharmaceutical composition thereof for use as a medicament.

[0059] Another aspect of the invention relates to the use of a compound of formula I as defined above or a pharmaceutical composition thereof for the manufacture of a medicament.

[0060] Another aspect of the present invention relates to a method for the treatment or prevention of a disease in a subject, particularly a human, in need thereof, which method comprises administering to a subject in need thereof an effective amount of a compound of formula I as defined above or a pharmaceutical composition thereof.

[0061] Another aspect of the invention relates to compounds of formula I as defined above for use in the treatment and / or prevention of immune diseases caused by a Th1 / Th2 imbalance.

[0062] In another embodiment, the invention relates to a compound of formula I as defined above for use in the treatment and / or prevention of a disease selected from metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune-mediated hepatitis, autoimmune diseases, transplant rejection pathologies, atherosclerosis, airway hyperactivity, asthma, allergic rhinitis and neurodegenerative diseases.

[0063] In another embodiment, the invention relates to a compound of formula I for the use as defined above, wherein said autoimmune disease is selected from rheumatoid arthritis, inflammatory bowel disease and gout.

[0064] In another embodiment, the invention relates to a compound of formula I for the use as defined above, wherein said neurodegenerative disorder is selected from Parkinson's disease or Alzheimer's disease.

[0065] As used herein, the term "treatment" refers to the elimination, alleviation, or amelioration of the cause or effects of a disease. For purposes of the present invention, treatment includes, but is not limited to, the alleviation, amelioration, or elimination of one or more symptoms of a disease; the reduction in the extent of a disease; the stabilization of the disease state (i.e., not worsening); the delay or slowing of the progression of a disease; the improvement or alleviation of the disease state; and the remission of a disease (whether partial or total).

[0066] As used herein, "prevention" refers to preventing the occurrence of a disease in a subject who has a predisposition or risk factors for the disease but who does not yet exhibit symptoms of the disease. Prevention also includes preventing the recurrence of a disease in a subject who has previously suffered from the disease.

[0067] Another aspect of the invention relates to a vaccine comprising an effective amount of a compound of formula I, or a pharmaceutical salt thereof, and a vaccinal agent.

[0068] In another embodiment, the present invention relates to a vaccine as defined above, wherein the vaccinal agent is selected from killed microorganisms, live attenuated microorganisms, toxoids and fragments of inactivated or attenuated microorganisms, synthetic peptide or glycopeptide constructs, ribonucleic acid (RNA)-based vaccines or deoxyribonucleic acid (DNA)-based vaccines.

[0069] In another embodiment, the invention relates to a vaccine as defined above, wherein the microorganism of the vaccinal agent is a virus, a bacterium or a fungus.

[0070] In another embodiment, the invention relates to a vaccine as defined above, wherein the toxoid is a tetanus or diphtheria toxoid.

[0071] In another embodiment, the present invention relates to a vaccine as defined above, wherein the RNA is messenger RNA (mRNA).

[0072] In another embodiment, the present invention relates to a vaccine as defined above, wherein the DNA is plasmid DNA (pDNA).

[0073] In another embodiment, the RNA- or DNA-based vaccine comprises a pharma- ceutically acceptable delivery system.

[0074] In another embodiment, the delivery system is non-viral or viral based.

[0075] In another embodiment, the non-viral based delivery system is selected from cationic lipids, cationic polymers, molecular-based systems, and nanoparticle-based systems.

[0076] In another embodiment, the viral-based delivery system is selected from an engineered adenoviral system and an engineered lentiviral system.

[0077] The therapeutic compositions of the invention can act as immunological adjuvants, enhancing the immune response elicited by a vaccine agent by stimulating the immune system, hi other embodiments, the therapeutic compositions can act as immunoablative agents, preventing or reducing unwanted immunological reactions to a vaccine in a treated subject.

[0078] In view of the above, the present invention provides novel hyperbranched glycolipids that are metabolically stable and can be selectively modified to optimize their immunomodulatory profile. The present invention also aims to provide a method for preparing said glycolipid mimics with complete α-anomer stereoselectivity. Furthermore, the present invention provides pharmaceutical products, such as vaccine formulations or anti-inflammatory agents, that contain the novel glycolipid mimics.

[0079] Thus, compounds in which the sugar moiety that is part of a multibranched immunomodulatory glycolipid has been converted to a multisubstituted 2-oxa-3-oxoindolizin-5-yl radical selectively induce the production of cytokines associated with Th1 or Th2 responses.

[0080] The compounds of the present invention can be prepared with complete α-anomeric stereoselectivity and are highly metabolically stable since they are not degraded by α-glycosidases that hydrolyze the glycosidic bonds of natural or synthetic glycolipids.

[0081] Furthermore, the compounds of the present invention are useful for modulating the Th1 / Th2 cell balance, either with respect to pro-inflammatory or anti-inflammatory cytokine producing cells, and they can be used, for example, as adjuvants in vaccine formulations or in the treatment and / or prevention of inflammation-related diseases, depending on the type of immune response (Th1 or Th2) induced.

[0082] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. Methods and materials similar or equivalent to those described herein may be used in the practice of this invention. Throughout this specification and claims, the word "comprises" and variations thereof are not intended to exclude other technical features, additives, ingredients, or steps. Additional objects, advantages, and features of the present invention will become apparent to those skilled in the art upon examination of this specification or may be learned by practice of the present invention. The following examples and figures are provided for illustrative purposes and are not intended to limit the present invention.

[0083] BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Suppression of LPS-induced inflammation (in vitro spleen cells). Spleen cells were treated simultaneously with the compound of the present invention and LPS to evaluate the inhibitory function of the compound against LPS-induced inflammation. Some compounds showed significant inhibitory function.

[0084] Figure 2. Suppression of LPS-induced inflammation in bone marrow derived macrophages (BMDMs in vitro). Compounds 12 and 27 were evaluated for their ability to suppress LPS-induced inflammation in bone marrow derived macrophages (BMDMs) and both showed significant suppression of IL-6 and TNFα.

[0085] Figure 3. Inhibition of LPS-induced inflammation in vivo. The in vivo ability of compound 12 in inhibiting LPS-induced inflammation in B6 mice was evaluated as shown in the scheme. Compound 12 was shown to significantly inhibit LPS-induced serum IL-6 and TNFα when injected twice at 30 min after LPS treatment.

[0086] Figure 4. The MAPK family ERK and p38, as well as STAT3, are inhibited by the novel compound. Using a multiplex bead array, we investigated how the novel compound exerts its inhibitory effect from the perspective of signal transduction, using compound 12, a representative compound of the present invention. Phosphorylation of the mitogen-activated protein kinases (MAPKs), ERK and p38, was significantly decreased by compound 12, but phosphorylation of JNK was not decreased. A significant decrease in phosphorylation of STAT3 was also observed.

[0087] Figure 5. Inhibition of αGalCer-induced inflammation (in vitro spleen cells). Spleen cells were treated simultaneously with the compound of the present invention and αGalCer to evaluate the inhibitory function of the compound against αGalCer-induced inflammation. Some compounds showed significant inhibitory function.

[0088] Figure 6. Shows the immune stimulating function of compounds (in vitro spleen cells). Spleen cells were treated with the compounds of the present invention alone to evaluate the immune stimulating function of the compounds. Compounds 12, 18, 22, 27 and 29 induced significant IFNγ secretion, and compound 8 induced significant IL-4 secretion.

[0089] Figure 7. Inhibition of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in vivo. The in vivo Th2 inflammation suppression ability of selected compounds 8, 12, 18 and 27 was evaluated using an OAV-induced AHR mouse model. Compounds 8, 12 and 18 were confirmed to suppress AHR.

[0090] Figure 8. Inhibition of OVA-induced airway inflammation in vivo (BALF). Bronchoalveolar lavage fluid (BALF) from mice in OAV-induced AHR experiments was examined for IL-13 and IL-4 levels. Compound 12 significantly inhibited both IL-13 and IL-4 levels. Compound 27 showed significant inhibition only for IL-13, and compound 18 showed significant inhibition only for IL-4.

[0091] Figure 9. Inhibition of OVA-induced airway inflammation in vivo (lung protein). IL-13 and IL-4 protein levels were examined in the lungs of mice from the OAV-induced AHR experiment. Compound 12 significantly inhibited the levels of IL-13 and IL-4. Compounds 8, 18, and 27 showed significant inhibition only for IL-13.

[0092] Figure 10. Inhibition of OVA-induced airway inflammation in vivo (lung mRNA). IL-13 and IL-4 mRNA levels were examined from the lungs of mice subjected to OAV-induced AHR experiments. Compound 12 significantly inhibited IL-13 mRNA levels.

[0093] Figure 11. Adjuvant function of compounds in vivo. The adjuvant function of selected compounds 8, 12, 18, 27, and 29 in vivo was evaluated by measuring serum levels of IFNγ and IL-4 induced after injection in B6 mice. Compounds 8, 12, 27, and 29 showed significant ability to induce both IFNγ and IL-4 2 hours after injection, and showed significant detectable levels of both cytokines even 18 hours after injection. Compound 18 only showed significant serum IFNγ levels at any time point.

[0094] Figure 12 shows that compound 12 promotes dendritic cell (DC) maturation in vivo. The ability of selected compounds 8, 12, 18, 27, and 29 to promote DC maturation in vivo was evaluated by measuring the mRNA level of DC maturation marker CD86 in the spleen of mice injected with the compounds of the present invention. It was observed that compound 12 induces a significant increase in CD86 mRNA.

[0095] Figure 13. Compound 12 promotes Th1 immune responses in vivo. The in vivo adjuvant potential of selected compounds 12 and 27 was demonstrated by increasing CD8 in the spleen of the OT-1 adoptive transfer mouse model as depicted in the scheme. + Compound 12 was evaluated for its ability to stimulate the proliferation of CD8 T cells. + It was observed that compound 12 induced the proliferation of T cells in mice, indicating that compound 12 can promote Th1 immune responses.

[0096] Figure 14. Compound 12 adjuvant is myeloid differentiation primary response 88 (MyD88) dependent and Th1 biased (in vitro spleen cells). The dependency of the biological function of the compounds of the present invention on functional MyD88 was examined using immune cells isolated from MyD88 knockout mice with representative compound 12. As a result, the ability of compound 12 to induce IFNγ in splenocytes isolated from MyD88 knockout mice was completely abolished. IL-4 was not detected with compound 12 treatment, indicating a Th1 biased nature.

[0097] Figure 15. The adjuvant activity of compound 12 is MyD88-dependent (bone marrow-derived dendritic cells-BMDCs-in vitro). Continuing the investigation of the dependency of the compounds of the present invention on functional MyD88 for biological function, it was found that the ability of bone marrow-derived dendritic cells (BMDCs) from MyD88 KO mice to produce IL-12p40 in response to compound 12 was significantly suppressed compared to BMDCs from wild-type mice. This effect was dose-dependent, and the difference became more pronounced with increasing concentrations.

[0098] Figure 16. Promotion of BMDC maturation by compound 12 is MyD88 dependent. Continuing our investigation into the dependency of the compounds of the present invention on functional MyD88 for biological function, we found that BMDC maturation induced by treatment with compound 12 was inhibited in BMDCs from MyD88-deficient mice.

[0099] [Example] (method) All reagents and solvents used in the preparations disclosed in the following examples were purchased commercially and used without further purification unless otherwise specified. Thin-layer chromatography (TLC) was performed using Silica gel 60 F. 254 Visualization was performed with UV light (λ 254 nm) on a Merck-coated aluminum sheet, and the cells were then stained with 10% ethanolic HO. 2 SO 4 , 0.1% ethanolic ninhydrin, and charring by heating at 100 °C. For preparative purposes, column chromatography was performed on Silice 60A.CC Chromagel (SDS 70-200, 35-70 μm). Optical rotation was measured with a Jasco P-2000 polarimeter at 20 ± 2 °C in 1 cm tubes using a sodium lamp (λ 589 nm). Elemental analysis was performed by the Instituto de Investigaciones Quimicas (Seville, Spain) using elemental analyzers Leco CHNS-932 o Leco TruSpec CHN. NMR experiments were performed on a Bruker 300 ADVANCE and 500 DRX at 300 (75.5), 500 (125.7, 202) MHz. One-dimensional TOCSY, two-dimensional COSY, HMQC and HSQC experiments were used to assist in NMR assignments. Chemical shift values ​​were calculated using tetramethylsilane (CDCl) as the solvent. 3) as an internal standard and expressed in ppm (parts per million). Coupling constant (J) values ​​are measured in Hz. Abbreviations indicating the multiplicity of signals are s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Mass spectrometry (high-resolution mass spectrometry) was performed on a Bruker Daltonics Esquire6000™ (LTQ-Orbitrap XL ETD). Samples were introduced through a solid probe heated to 30-280°C. ESI (electrospray ionization) was used as the ionization source, and methanol was used as the solvent. Samples were directly injected into a Cole-Parmer syringe at a flow rate of 2 μl / min. Ions were scanned between 300 and 3000 Da at a scan rate of 13000 Da / s with unit resolution using resonance ejection at a multipole resonance of one-third of the radio frequency (Ω = 725 kHz).

[0100] (material) In the illustrative disclosure, the following precursors used in the synthesis of certain compounds of the invention were obtained by known methods: (1R)-1,2,3,4-Tetra-O-acetyl-5N,6O-oxomethylideneojirimycin (32) was prepared as described in VM Diaz Perez, MI Garcia Moreno, C. Ortiz Mellet, J. Fuentes, JC Diaz Arribas, FJ Canada and JM Garcia Fernandez, J. Org. Chem., 2000, 65, 136-143. [ka] (1R)-1,2,3,4-Tetra-O-acetyl-5N,6O-oxomethylidenegalactonojirimycin (33) was prepared as described by P. Diaz Perez, MI Garcia-Moreno, C. Ortiz Mellet and JM Garcia Fernandez, Eur. J. Org. Chem., 2005, 14, 2903-2913). [ka] The biantennary lipid acceptor 34 was prepared as described in J. Bi, J. Wang, K. Zhou, Y. Wang, M. Fang and Y. Du, ACS Med. Chem. Lett., 2015, 6, 476-480. [ka] Sphingosine precursor 35 was prepared as described in N. Veerapen, M. Brigl, S. Garg, V. Cerundolo, LR Cox, MB Brenner, GS Besra, Bioorg. Med. Chem. Lett., 2009, 19 4288-4291. [ka] L-serine acceptor 36 was prepared as described in L. De Huang, HJ Lin, PH Huang, WC Hsiao, LV Raghava Reddy, SL Fu and CC Lin, Org. Biomol. Chem., 2011, 9, 2492-2504. [ka] 5-Azido-3-O-benzyl-5-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (42) was prepared as described in M. Aguilar-Moncayo, C. Ortiz Mellet, JM Garcia Fernandez, and MI Garcia-Moreno. J. Org. Chem. 2009, 74, 3595-3598. [ka] α-GalCer (αGC, KRN7000) was purchased from Funakoshi (Tokyo, Japan). RPMI1640, DMEM, newborn calf serum (NBCS) and red blood cell (RBC) lysis buffer were purchased from Gibco (Waltham, MA, USA). Fetal bovine serum (FBS) was purchased from HyClone (Logan, UT, USA). Recombinant mouse IL-2 and GM-CSF were purchased from BioLegend (San Diego, CA, USA) and PeproTech (Rocky Hill, NJ, USA). Recombinant human IL-2 was purchased from eBioscience (San Diego, CA, USA). Ovalbumin (OVA) was purchased from Worthington Biochemicals (Freehold, NJ, USA).

[0101] (mouse) C57BL / 6 and BALB / c female mice aged 8–10 weeks were purchased from the National Laboratory Animal Center (Taipei, Taiwan). All animals were kept under specific pathogen-free conditions.

[0102] (In vitro culture of mouse splenocytes and human peripheral blood mononuclear cells (PBMCs)) Whole spleens were surgically removed from mice and mechanically dissociated into single-cell suspensions of splenocytes, which were cultured in complete RPMI 1640 medium (cRPMI).Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers were obtained from whole blood by gradient centrifugation using Histopaque-1077 (Sigma-Aldrich).

[0103] (In vivo treatment) For the ovalbumin (OVA) test, mice were sensitized intraperitoneally (ip) with 50 μg OVA in 2% Alhydrogel adjuvant (InvivoGen). On day 7 after sensitization, mice were sensitized three times with 50 μg OVA, either daily or every other day. Mice were sacrificed the day after the final OVA challenge. + A scheme of the OT-1 adoptive transfer mouse model for investigating T cell proliferation is shown in FIG.

[0104] (Measurement of Airway Hyperresponsiveness (AHR)) Mice were anesthetized with 100 mg pentobarbital (Sigma-Aldrich) per kg body weight, tracheotomized, and mechanically ventilated via a FinePointe RC system (Buxco Research Systems, Wilmington, NC). Pulmonary function was assessed by measuring pulmonary resistance and dynamic compliance in response to increasing doses of aerosolized methacholine (1.25–40 mg / mL, Sigma-Aldrich).

[0105] (Collection and analysis of bronchoalveolar lavage fluid (BALF)) After exposing the trachea, the lungs were lavaged twice with 1 mL of PBS supplemented with 2% fetal calf serum (FCS). BALF was pooled, and BAL cells were pelleted by centrifugation and fixed on cytospin slides. Slides were stained with Diff-Quik solution (Polysciences Inc), and BAL differential cell counts were calculated.

[0106] (Flow Cytometry) Single cell suspensions were stained with the fixable viability dye eFluor® 780 (eBioscience) for 30 min at 4°C and Fc receptors were blocked with anti-CD16 / 32 (BioLegend) blocking antibody before surface staining with monoclonal antibodies.

[0107] (statistics) Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). Statistical analysis was performed using Student's t-test and two-way analysis of variance (ANOVA).

[0108] [Example 1. Synthesis of Compound 1]

[0109] A solution of 32 (20 mg, 0.05 mmol) and 34 (0.10 mmol) was added to BF at 0 °C under Ar atmosphere. 3 -OEt 2 (32 μL, 0.25 mmol) was added. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:4→1:3→1:2 EtOAc-cyclohexane). Yield: 48 mg (66%). f =0.44 (1:2 EtOAc-cyclohexane). [α] D +42.2(c1.0inDCM). 1 H NMR (500 MHz, CDCl 3 ):δ8.01-7.34(m,10H,CH-arom),6.84(d,1H,J NH,2’ =9.3Hz,NH),5.70(dd,1H,J 3’,4’ =9.5Hz,J 2’,3’ =3.0Hz,H-3'),5.46(t,1H,J 2,3 =J 3,4 =10.0Hz,H-3),5.31(dt,1H,J 4’,5’ =9.3Hz,H-4'),5.19(d,1H,J 1,2=3.8Hz,H-1),4.94-4.87(m,2H,H-2,H-4),4.61(m,1H,H-2'),4.40(t,1H,J 5,6a =J 6a,6b =8.9Hz,H-6a),4.20(dd,1H,J 5,6b =7.4Hz,H-6b),3.90(m,1H,H-5),3.71(dd,1H,J 1a’,1b’ =11.0Hz,J 1a’,2’ =2.8Hz,H-1a'),3.60(dd,1H,J 1a’,2’ =3.81Hz,H-1b'),2.36(t,2H, 3 J H,H =7.4Hz , COCH 2 ),2.09,2.07,1.97(3s,9H,CH 3 CO), 1.90-1.23(m,75H,CH 2 ,CH 2 CH 3 ). 13 CNMR (125.7MHz, CDCl 3 ): δ173.2,169.9,169.8(COエステル),155.0(COカルバメート),133.4-128.4(C-arom),79.9(C-1),74.1(C-4'),72. 5(C-4),71.8(C-3'),70.0(C-4),69.3(C-3),68.1(C-1'),66.8(C-6),51.8(C-5),48.6(C-2'),36.7(COCH 2 ),31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). ESIMS: m / z 1239.80 [M+Na] + HRMS (ESI) calculation for C 71 H 112 N 2 O 14 Na 1239.8006. Found 1239.8006.

[0110] [Example 2. Synthesis of compound 2]

[0111] Compound 2 was obtained by treating a solution of 1 in MeOH (2.6 mL) with 1M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Column chromatography 100:10:1 DCM-MeOH-H 2 O. Yield: 26 mg (quantitative). f = 0.64(70:10:1DCM-MeOH-H 2 O). [α] D +16.76(c 0.81 10:1 DCM-MeOH). 1 H NMR (700 MHz, 2:1 CDCl 3 -CD 3 OD): δ 5.08 (d, 1H, J 1,2 =4.2Hz,H-1),4.50(t,1H,J 5,6a =J 6a,6b =8.6Hz,H-6a),4.23(dd,1H,J 5,6b =6.1Hz,H-6b),4.20(m,1H,H-2'),3.80(dd,1H,J 1a’,1b’ =10.3Hz,J 1a’,2’ =4.3Hz,H-1a'),3.72(m,1H,H-5),3.66(dd,1H,J 1b’,2’ =4.5Hz,H-1b'),3.60(t,1H,J 2,3 =J 3,4 =9.3Hz,H-3),3.55(t,1H,J 2’,3’ =J 3’,4’ =6.0Hz.H-4'),3.50(m,1H,H-3'),3.42(dd,1H,J 2,3 =9.7Hz,H-2),3.29(t,1H,J 4,5 =9.3Hz,H-4),2.19(t,2H, 3 J H,H =7.4Hz , COCH 2 ), 1.24(m,72H,CH 2 ),0.85(t,6H, 3 J H,H =6.9Hz , CH 3 ). 13 C NMR (125.7 MHz, 2:1 CDCl3 -CD 3 OD): δ173.4 (CO ester), 156.1 (CO carbamate), 81.7 (C-1), 73.9 (C-3'), 73.2 (C-4), 72.4 (C-3), 71.3 (C-4'), 70.6 (C-2), 67.7 (C-1'), 66.3 (C-6), 52.4 (C-5), 49.2 (C-2'), 35.6-13.0 (CH 2 ,CH 2 CH 3 ). HRMS(ESI):m / z905.71[M+Na] + HRMS(ESI) calcd for C 51 H 98 N 2 O 9 Na 905.7165. Found 905.7147.

[0112] [Example 3. Synthesis of compound 3]

[0113] Compound 3 was obtained by coupling of glycosyl donor 32 with lipid acceptor 37. Acceptor 37 was prepared from 35 according to Scheme 6 below. [ka] DMF-H 2 A solution of the azide derivative 35 (200 mg, 0.583 mmol) in 4:1 O (5.8 mL) was diluted with 1-decyne (157 μL, 0.874 mmol), CuSO 4 (13 mg, 0.087 mmol) and ascorbic acid (30 mg, 0.174 mmol) were added and the solution was stirred overnight. The solvent was evaporated and the resulting residue was purified by column chromatography eluting with 1:4 EtOAc-cyclohexane to give 37. Yield: 361 mg (90%). f = 0.4 (1:4 EtOAc-cyclohexane). 1 H NMR (500 MHz, CDCl 3 ): δ = 8.05-7.30 (m, 11H, CH-arom, CH-triazole), 5.86 (dd, 1H, J 3,4 =8.7Hz,J2,3 =3.1Hz,H-3),5.22(s,1H,OH),4.96(m,2H,H-2,H-4),4.07(dd,1H,J 1a,1b =12.5Hz,J 1a,2 =4.6Hz,H-1a),3.96(dd,1H,J 1b,2 =2.7Hz,H-1b),2.66(t,2H, 3 J H,H =7.4Hz , CH 2 ), 1.68-0.80(m,49H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ171.2, 166.1(CO), 149.0(C-4 triazole), 136.5-128.4(C-arom), 121.1(C-5 triazole), 73.3(C-3), 72.1(C-4), 61.6(C-1), 61.3(C-2), 31.9-14.0(CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for C 42 H 64 N 3 O 5 690.4840. Found 690.4838.

[0114] In a subsequent step, a solution of 32 (20 mg, 0.05 mmol) and 37 (0.10 mmol) in DCM (1.2 mL) was treated with BF 3 -OEt 2 (32 μL, 0.25 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the target compound 3. Yield: 33 mg (65%). f =0.5 (1:2 EtOAc-cyclohexane). [α] D +13.04 (during c1.0 DCM). 1H NMR (500 MHz, CDCl 3 ): δ 7.94-7.33 (m, 10H, CH-arom), 7.60 (s, 1H, CH-triazole), 5.94 (dd, 1H, J 3’,4’ =8.5Hz,J 2’,3’ =3.5Hz,H-3'),5.31(t,1H,J 2,3 =J 3,4 =10.0Hz,H-3),5.20(m,1H,H-2'),5.17(d,1H,J 1,2 =3.8Hz,H-1),4.95(dt,1H,J 4’,5’ =9.3Hz,H-4'),4.75(m,2H,H-2,H-4),4.31(t,1H,J 5,6a =J 6a,6b =8.9Hz,H-6a),4.11(dd,1H,J 5,6b =7.5Hz,H-6b),3.93(m,2H,H-1a',H-1b'),3.49(m,1H,H-5),2.69(t,2H, 3 J H,H =7.4Hz , COCH 2 ), 1.95, 1.94, 1.89 (3s, 9H, CH 3 CO), 1.62-0.80(m, 46H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ169.9, 169.8, 169.4, 165.9, 164.9 (CO ester), 155.4 (CO carbamate), 149.2 (C-4 triazole), 133.7-128.2 (C-arom), 120.8 (C-5 triazole), 79.5 (C-1), 72.9 (C-4'), 72.3 (C-4), 71.2 (C-3'), 69.8 (C-2), 68.8 (C-3), 66.9 (C-1'), 66.8 (C-6), 59.7 (C-2'), 51.5 (C-2'), 31.9 (COCH 2 ), 30.1-22.6(CH 3 CO,CH 2 ,CH 2 CH 3 ).HRMS(ESI) calcd for C 55H 78 N 4 O 13 Na 1025.5458. Found 1025.5450.

[0115] [Example 4. Synthesis of compound 4]

[0116] Compound 4 was obtained by treating a solution of 3 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. 2 O. Yield: 22 mg (quantitative). f =0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +15.8 (c1.0 in MeOH). 1 H NMR (500CD 3 OD): δ 7.88 (s, 1H, CH-triazole), 5.12 (q, 1H, J 1’,2’ =J 2’,3’ =5.7Hz,H-2'),5.05(d,1H,J 1,2 =4.2Hz,H-1),4.51(t,1H,J 5,6a =J 6a,6b =8.6Hz,H-6a),4.22(dd,1H,J 5,6b =6.1Hz,H-6b),4.18(d,1H,J 3’,4’ =5.8Hz,H-4'),3.86(dd,1H,J 2,3 =8.0Hz,J 3,4 =5.1Hz,H-3),3.50(m,3H,H-5,H1a',H1b'),3.40(dd,1H,H-2),3.37(m,1H,H-3'),3.29(t,1H,J 4,5 =9.3Hz,H-4),2.71(t,2H, 3 J H,H =7.4Hz , COCH 2 ), 1.69-0.91(m,46H,CH 2 ,CH 2 CH 3 ). 13C NMR (125.7MHz, CD 3 OD): δ157.1 (CO carbamate), 147.7 (C-4 triazole), 121.7 (C-5 triazole), 82.9 (C-1), 74.5 (C-3), 74.1 (C-4), 73.0 (C-1'), 71.5 (C-3', C-2), 67.4 (C-4'), 67.1 (C-6), 61.7 (C-2'), 53.4 (C-5), 32.4-13.0 (CH 2 ,CH 2 CH 3 ). ESIMS: m / z 669.37 [M+H] + Anal.calcd.for C 35 H 64 N 4 O 8 S:C62.85,H9.64,N8.38. Found C63.23, H9.69, N8.31.

[0117] [Example 5. Synthesis of Compound 5]

[0118] To a solution of 33 (20 mg, 0.05 mmol) and 34 (0.10 mmol) in DCM (1.2 mL) was added BF 3 -OEt 2 (32 μL, 0.25 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:4→1:3→1:2 EtOAc-cyclohexane). Yield: 44 mg (77%). f =0.47 (1:2 EtOAc-cyclohexane). [α] D +41.41 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ8.01-7.47(m,10H,CH-arom),6.42(d,1H,J NH,2’ =9.6Hz,NH),5.63(dd,1H,J 3’,4’ =9.1Hz,J 2’,3’ =2.9Hz,H-3'),5.40(t,1H,J3,4 =J 4,5 =2.4Hz,H-4),5.24-5.21(m,2H,H-4’,H-1),5.25(dd,1H,J 2,3 =10.8Hz,H-3),5.13(dd,1H,J 1,2 =4.3Hz,H-2),4.64-4.58(m,1H,H-2’),4.36(t,1H,J 5,6a =J 6a,6b =9.0Hz,H-6a),4.19-4.15(m,1H,H-5),4.00(dd,1H,J 5,6b =5.9Hz,H-6b),3.71(dd,1H,J 1a’,1b’ =11.0Hz,J 1a’,2’ =2.9Hz,H-1a’),3.62(dd,1H,J 1a’,2’ =3.9Hz,H-1b’),2.30(t,2H, 3 J H,H =7.7Hz , COCH 2 ),2.14,1.99,1.95(3s,9H,CH 3 CO),1.80-0.80(m,75H,CH 2 ,CH 2 CH 3 )。 13 C NMR(125.7MHz,CDCl 3 ):δ173.1(COアミド),170.2,169.9(COエステル),155.8(COカルバメート),133.5-128.4(C-arom),80.6(C-1),74.0(C-4’),72.3(C-3’),68.6(C-1’),68.0(C-4),67.9(C-3),66.9(C-2),63.1(C-6),50.7(C-5),48.7(C-2’),36.8-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 )。HESIMS:m / z1239.80[M+Na] + 。HRMS(ESI)calcd for C 71 H 112 N 2 O 14 Na 1239.8006。Found 1239.7996。

[0119] [Example 6. Synthesis of Compound 6]

[0120] Compound 6 was obtained by treating a solution of 5 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. 2 O. Yield: 18 mg (quantitative). f =0.65(70:10:1 DCM-MeOH-H 2 O). [α] D +7.9 (c0.6 in DCM-MeOH). 1 H NMR (500 MHz, 6:1 CDCl 3 -CD 3 OD): δ 5.09 (d, 1H, J 1,2 =4.1Hz,H-1),4.41(dd,1H,J 5,6a =J 6a,6b =8.9Hz,H-6a),4.31(t,1H,H-6b),4.17(q,1H,J 1’,2’ =J 2’,3’ =4.6Hz,H-2'),3.94(m,1H,H-5),3.82(dd,1H,J 1a’,1b’ =10.3Hz,H-1a'),3.81(t,1H,J 3,4 =J 4,5 =2.2Hz,H-4),3.75(dd,1H,J 2,3 =9.7Hz,J 1,2 =4.1Hz,H-2),3.69(dd,1H,H-3),3.64(m,1H,H-1b'),3.54-3.42(m,2H,H-4',H-3'),2.14(t,2H, 3 J H,H =7.4Hz , COCH 2 ), 1.63-0.82(m,75H,CH 2 ,CH 2 CH 3 ). 13 C NMR (150.9 MHz, 6:1 CDCl 3 -CD 3OD): δ 173.4 (CO amide), 156.1 (CO carbamate), 82.7 (C-1), 74.9 (C-3'), 72.2 (C-4'), 69.8 (C-3), 68.4 (C-4), 68.4 (C-1'), 67.9 (C-2), 63.5 (C-6), 52.5 (C-5), 50.2 (C-2'), 36.5 (COCH 2 ), 34.0-13.8(CH 2 ,CH 2 CH 3 ).ESIMS: m / z 905.71[M+H] + HRMS(ESI) calcd for C 51 H 98 N 2 O 9 Na 905.7165. Found 905.7151.

[0121] [Example 7. Synthesis of compound 7]

[0122] To a solution of 33 (20 mg, 0.05 mmol) and 37 (0.10 mmol) in DCM (1.2 mL) was added BF 3 -OEt 2 (32 μL, 0.25 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane). Yield: 35 mg (70%). f =0.47 (1:2 EtOAc-cyclohexane). [α] D +14.10 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ7.94-7.36(m,10H,CH-arom),5.91(dd,1H,J 3’,4’ =7.8Hz,J 2’,3’ =4.1Hz,H-3'),5.28(bd,2H,H-1,H-4),5.16(m,1H,H-2'),5.10(dd,1H,,J 2,3 =10.8Hz,J 1,2=4.3Hz,H-2),4.98(m,2H,H-3,H-4'),4.29(t,1H,J 5,6a =J 6a,6b =9.1Hz,H-6a),4.01(dd,1H,J 5,6b =3.1Hz,H-6b),3.91(m,2H,H-1a',H-1b'),3.79(m,1H,H-5),2.66(m,2H,CH 2 ), 2.07, 1.91, 1.86 (3s, 9H, CH 3 CO), 1.54-0.80(m, 46H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ170.1, 170.0, 169.6, 166.0, 164.9 (CO ester), 155.6 (CO carbamate), 149.2 (C-4 triazole), 139.1-128.4 (C-arom), 120.3 (C-5 triazole), 80.1 (C-1), 72.9 (C-4'), 71.6 (C-4), 67.9 (C-3'), 67.8 (C-2), 66.9 (C-3), 66.7 (C-1'), 63.0 (C-6), 59.9 (C-2'), 50.4 (C-5), 31.9 (COCH 2 ), 30.0-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for C 55 H 78 N 4 O 13 Na 1025.5458. Found 1025.5450.

[0123] [Example 8. Synthesis of compound 8]

[0124] Compound 8 was obtained by treating a solution of 7 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. 2O. Yield: 23mg (quantitative). R f =0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +16.2 (c1.0 in MeOH). 1 H NMR (500CD 3 OD): δ7.89(s,1H,CH-トリアゾール),5.11(m,2H,H-1,H-2'),4.38(d,2H,H-4,H-6a),4.16(d,2H,J 5,6b =5.7Hz,H-3,H-6b),3.87(d,1H,J 3’,4’ =5.1Hz,H-4'),3.79(m,3H,H-1a',H-1b',H-3'),3.66(dd,1H,H-2),3.38(m,1H,H-5),2.71(t,2H, 3 J H,H =7.4Hz , COCH 2 ),1.69-0.91(m,46H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7 MHz, CD 3 OD): δ157.8(COカルバメート), 147.7(C-4 トリアゾール), 121. 7(C-5 Torrent),83.1(C-1),74.4(C-3),71.5(C-4), 69.9(C-1'),69.0(C-3')67.6(C-2),67.2(C-4'),63.7(C-6),61.8(C-2'),52.9(C-5),32.3-13.0(CH 2 ,CH 2 CH 3 ). ESIMS: m / z 669.33[M+H] + . Anal.calcd.for C 35 H 64 N 4 O 8 S:C62.85,H9.64,N8.38. Found C63.30,H8.71,N8.33.

[0125] [Example 9. Synthesis of Compound 9]

[0126] Compound 9 was obtained by coupling of glycosyl donor 33 with lipid acceptor 38. Acceptor 38 was prepared from 35 according to Scheme 7 below. [ka] DMF-H 2 A solution of the azide derivative 35 (150 mg, 0.272 mmol) in 4:1 O (3.7 mL) was diluted with 1-tetradecyne (133 μL, 0.544 mmol), CuSO 4 (10 mg, 0.041 mmol) and ascorbic acid (16 mg, 0.082 mmol) were added and the solution was stirred overnight. The solvent was evaporated and the resulting residue was purified by column chromatography eluting with 1:4 EtOAc-cyclohexane to give 38. Yield: 120 mg (60%). f = 0.4 (1:4 EtOAc-cyclohexane). 1 H NMR (300 MHz, CDCl 3 ): δ = 7.98-7.18 (m, 11H, CH-arom, CH-triazole), 5.86 (dd, 1H, J 3,4 =8.7Hz,J 2,3 =3.1Hz,H-3),4.96(m,2H,H-2,H-4),4.06(dd,1H,J 1a,1b =12.5Hz,J 1a,2 =4.6Hz,H-1a),3.95(dd,1H,J 1b,2 =2.7Hz,H-1b),2.65(t,2H, 3 J H,H =7.4 Hz , CH 2 ), 1.60-0.80(m,58H,CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl 3 ): δ166.1, 165.9(CO), 133.9-128.4(C-arom), 121.1(C-triazole), 73.3(C-3), 72.1(C-4), 61.6(C-1), 61.3(C-2), 31.9-14.0(CH 2 ,CH 2CH 3 ).HRMS(ESI) calcd for C 46 H 72 N 3 O 5 746.5466. Found 746.5461.

[0127] In a subsequent step, a solution of 33 (27 mg, 0.07 mmol) and 38 (0.10 mmol) in DCM (1.2 mL) was treated with BF 3 -OEt 2 (32 μL, 0.35 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried over 1000 ml, filtered and concentrated. The residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the target compound 9. Yield: 54 mg (70%). f =0.50 (1:2 EtOAc-cyclohexane). [α] D +17.15 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ): δ 7.94-7.36 (m, 11H, CH-arom, C-triazole), 5.90 (dd, 1H, J 3’,4’ =7.2Hz,J 2’,3’ =4.2Hz,H-3'),5.28(bd,2H,H-1,H-4),5.16(m,1H,H-2'),5.08(dd,1H,J 2,3 =10.8Hz,J 1,2 =4.3Hz,H-2),4.98(m,2H,H-3,H-4'),4.29(t,1H,J 5,6a =J 6a,6b =9.1Hz,H-6a),4.01(dd,1H,J 5,6b =2.5Hz,H-6b),3.91(m,2H,H-1a',H-1b'),3.79(m,1H,H-5),2.66(m,2H,CH 2 ), 2.07, 1.91, 1.86 (3s, 9H, CH 3 CO), 1.58-0.80(m, 55H, CH 2 ,CH 2 CH3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ170.1, 170.0, 169.6, 166.0, 164.9(CO), 155.6(CO carbamate), 149.2-128.5(C-arom), 120.4(C-triazole), 80.1(C-1), 72.8(C-4'), 71.6(C-4), 67.9(C-3'), 67.8(C-2), 66.9(C-3), 66.7(C-1'), 63.0(C-6), 59.9(C-2'), 50.4(C-5), 31.9(COCH 2 ), 29.7-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 59 H 86 N 4 NaO 13 ] + 1081.6084; found 1081.6082.

[0128] [Example 10. Synthesis of compound 10]

[0129] Compound 10 was obtained by treating a solution of 9 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. 2 Column chromatography using O. Yield: 65 mg (quantitative). f =0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +10.2 (c1.0 in MeOH). 1 H NMR (500CD 3 OD): δ 7.87 (s, 1H, CH-triazole), 5.08 (m, 2H, H-1, H-2'), 4.36 (d, 2H, H-4, H-6a), 4.14 (d, 2H, J 5,6b =5.7Hz,H-3,H-6b),3.86(dd,1H,J 3’,4’=5.4Hz,H-4'),3.78(m,3H,H-1a',H-1b',H-3'),3.65(dd,1H,J 2,3 =9.9Hz,J 1,2 =3.1Hz,H-2),3.36(m,1H,H-5),2.69(t,2H, 3 J H,H =7.4Hz,COCH 2 ), 1.67-0.91(m,57H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CD 3 OD): δ161.7 (CO carbamate), 151.6, 125.6 (C-triazole), 87.0 (C-1), 78.3 (C-3), 75.4 (C-4), 73.8 (C-1'), 72.9 (C-3') 71.5 (C-2), 71.5 (C-4'), 67.6 (C-6), 65.7 (C-2'), 56.9 (C-5), 35.6-16.9 (CH 2 ,CH 2 CH 3 ). ESIMS: m / z 725.65 [M+H] + .

[0130] [Example 11. Synthesis of compound 11]

[0131] The synthesis of compound 11 involves a first conjugation between a glycosyl donor 32 and an acceptor 36 to give intermediate 39. [ka] A solution of 32 (20 mg, 0.05 mmol) in dry DCM (1.2 mL) was treated with N-modified-L-serine 36 (0.10 mmol) and BF at 0 °C under Ar atmosphere. 3 -OEt 2 (32 μL, 0.25 mmol) was added. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give 39. Yield: 106 mg (63%). f 0.60 (2:1 EtOAc-cyclohexane). [α] D +37.46 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 ):δ=7.77-7.20(m,12H,CH-arom),6.30(t,1H,J NH,CH2 =5.6Hz,NHCH 2 ), 5.78(d.1H,J NH,CH =8.0Hz,NHFmoc),5.48(m,2H,H-1,H-3),4.94(m,1H,H-4),4.92(dd,1H,J 2,3 =6.2Hz,J 1,2 =4.6Hz,H-2),4.44(m,4H,H-6a,OCH 2 CH,CH 2 Fmoc),4.25(m,2H,H-5,CHFmoc),3.98(m,1H,H-6b),3.78(m,2H,OCH 2 CH), 3.27(m, 2H, NHCH 2 ), 2.09, 2.05, 2.04(3s, 9H, CH 3 CO), 1.55-0.89(m, 25H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl 3 ): δ = 169.9, 169.7, 169.0 (CO), 155.7 (CO carbamate), 143.6-120.0 (C-arom), 79.5 (C-1), 72.4 (OCH 2 CH),70.2(C-4),69.1(C-2),68.9(C-3),67.3(C-6),67.0(CH 2 Fmoc), 54.2(OCH 2 CH),51.7(CHFmoc),47.0(C-5),39.9(NHCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH3 ).ESIMS: m / z=830.38[M+Na] + HRMS(ESI) calcd for [C 43 H 57 O 12 N 3 Na] + 830.3834. Found 830.3824.

[0132] In a subsequent step, piperidine (131 μL, 1 mL / mmol) was added to a stirred solution of 39 (100 mg, 0.131 mmol) in DMF (1.5 mL). After 1 h, the mixture was evaporated and the crude product was dissolved in DMF (1.8 mL) and treated with dodecanoyl chloride (47 μL, 0.196 mmol) and Et 3 N (37 μL, 0.262 mmol) was added. The mixture was stirred for 16 h and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give the target compound 11. Yield: 75 mg (65%, 2 steps). R f 0.40 (1:1 EtOAc-cyclohexane). [α] D +27.98 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 ): δ = 6.36 (d, 1H, J NH,CH =7.8Hz,NHCH),6.29(bt,1H,J NH,CH =5.6Hz,NHCH 2 ), 5.46(d,1H,J 1,2 =4.7Hz,H-1),5.45(m,1H,H-3),4.94(t,1H,J 4,5 =9.4Hz,H-4),4.91(bdd,1H,J 2,3 =9.9Hz,H-2),4.60(m,1H,OCH 2 CH), 4.49(t,1H,J 5,6a =J 5,6b =8.5Hz,H-6a),4.27(bdd,1H,H-6b),3.99(m,1H,H-5),3.76(m,2H,OCH 2 CH), 3.28(m, 2H, NHCH 2 ), 2.24(m,2H,COCH 2), 2.11, 2.06, 2.04(3s, 9H, CH 3 CO), 1.64-0.89(m, 48H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl 3 ): δ = 173.3, 169.9, 169.6, 169.2 (CO), 155.8 (CO carbamate), 79.6 (C-1), 72.5 (C-4), 70.2 (C-2), 68.9 (C-3), 68.8 (OCH 2 CH), 67.1(C-6), 52.3(OCH 2 CH), 51.8(C-5), 39.8(NHCH 2 ), 36.5(COCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). ESIMS: m / z=768.50[M+H] + HRMS(ESI) calcd for [C 40 H 69 O 11 N 3 Na] + 790.4824. Found 790.4810.

[0133] [Example 12. Synthesis of compound 12]

[0134] Compound 12 was obtained by treating a solution of 11 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration and evaporation to dryness. Yield: 60 mg (quantitative). f 0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +14.52 (c1.0 in DCM:MeOH). 1 H NMR (500MHz, 1:1 CD 3 OD-CDCl 3 ): δ = 5.00 (d, 1H, J 1,2=4.0Hz,H-1),4.44(m,1H,H-6a),4.15(dd,1H,J 5,6b =9.5Hz,J 6a,6b =6.3Hz,H-6b),3.64(m,1H,H-5),3.59(m,3H,H-4,OCH 2 CH),3.49(bt,1H,J 2,3 =10.7Hz,H-3),3.36(dd,1H,J 2,3 =9.9Hz,H-2),3.25(m,1H,OCH 2 CH),3.11(m,2H,NHCH 2 ),2.15(t,2H,J H,H =7.0Hz,COCH 2 ),1.53-0.79(m,48H,CH 2 ,CH 2 CH 3 )。 13 C NMR(125.7MHz,1:1 CD 3 OD-CDCl 3 ):δ=174.9,170.5(CO),157.4(COカルバメート),82.7(C-1),74.4(C-3),73.5(OCH 2 CH),71.9(C-2),68.5(C-5),67.5(C-6),53.6(C-4),52.7(OCH 2 CH),39.9(NHCH 2 ),36.3(COCH 2 ),31.9-14.1(CH 2 ,CH 2 CH 3 )。ESIMS:m / z=664.45[M+Na] + 。HRMS(ESI)calcd for [C 34 H 63 O 8 N 3 Na] + 664.4507。Found 664.4511。Anal.calcd.for C 34 H 63 N 3 O 8 :C 63.62,H 9.89,N 6.55。Found C 63.41,H 9.74,N 6.29。

[0135] [Example 13. Synthesis of compound 13]

[0136] To a stirred solution of 38 (100 mg, 0.131 mmol) in DMF (1.5 mL) was added piperidine (131 μL, 1 mL / mmol). After 1 h, the mixture was evaporated and the crude product was dissolved in DMF (1.8 mL) and treated with octyl isothiocyanate (38 μL, 0.196 mmol) and Et 3 N (37 μL, 0.262 mmol) was added. The mixture was stirred for 16 h and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give 13. Yield: 59 mg (59%, 2 steps). f 0.50 (1:1 EtOAc-cyclohexane). [α] D +18.24 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ=6.63(bs,2H,NH),5.39(m,2H,H-1,NH),4.88(t,1H,J 2,3 =J 3,4 =9.7Hz,H-3),4.86(t,1H,J 4,5 =9.4Hz,H-4),4.40(t,1H,J 5,6a =J 5,6b =8.6Hz,H-6a),4.18(bdd,1H,H-6b),3.94(bdd,1H,H-5),3.85(m,1H,CH),3.73(dd,1H,J 1,2 =6.0Hz,H-2),3.18(m,2H,NHCH 2 ), 2.04, 1.98, 1.95(3s, 9H, CH 3 CO), 1.57-0.81(m, 38H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3): δ = 181.4 (CS), 169.9, 169.7, 169.6 (CO ester), 156.0 (CO carbamate), 79.8 (C-1), 72.4 (C-4), 70.2 (C-2), 69.7 (C-3), 68.7 (CH), 67.1 (C-6), 51.9 (C-5), 39.9 (NHCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 37 H 64 N 4 O 10 SNa] + 779.4235. Found 779.4229.

[0137] [Example 14. Synthesis of compound 14]

[0138] Compound 14 was obtained by treating a solution of 13 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 49 mg (quantitative). f 0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +18.25 (c1.0 in MeOH). 1 H NMR (500MHz, CD 3 OD): δ = 5.02 (d, 1H, J 1,2 =4.0Hz,H-1),4.44(m,1H,J 5,6a =9.2Hz,J 6a,6b =8.6Hz H-6a), 4.15(dd, 1H, J 5,6b =6.1Hz,H-6b),3.72(m,2H,H-5,CH),3.61(m,2H,CH 2 ), 3.51(t,1H,J 3,4 =10.4Hz,H-4),3.36(dd,1H,J 2,3 =9.6Hz,H-2),3.24(m,1H,H-3),3.14(m,2H,NHCH 2 ), 1.47-0.82(m,38H,CH2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CD 3 OD):δ=170.9(CO),157.2(CO carbamate),82.4(C-1),74.1(C-3),73.0(C-4),71.6(C-2),68.2(C-5),67.1(C-6),53.4(CH),39.2(NHCH 2 ), 31.6-13.0(CH 2 ,CH 2 CH 3 ). ESIMS: m / z=631.25[M+H] + Anal.calcd.for C 31 H 58 N 4 O 7 S:C 59.02,H 9.27,N 8.88,S 5.08.Found C 58.75,H 8.98,N 8.54,S 4.72.

[0139] [Example 15. Synthesis of compound 15]

[0140] Compound 15 was obtained by coupling of glycosyl donor 32 with thiol acceptor 40. Acceptor 40 was prepared from commercially available N-Fmoc-S-trityl-L-cysteine ​​by the procedure described below. [ka] To a stirred solution of N-Fmoc-S-trityl-L-cysteine ​​(10 g, 17 mmol) in THF (130 mL) was added HOBt (2.3 g, 17 mmol), DCC (3.5 g, 17 mmol) and dodecylamine (3.1 g, 17 mmol) at ambient temperature. The mixture was stirred overnight, filtered and concentrated. The crude mixture was dissolved in THF (132 mL) and piperidine (20 mL) was added. The reaction was stirred for 20 min. The solvent was then removed under reduced pressure and co-evaporated with MeOH (3×20 mL) to remove traces of piperidine. The free amine (500 mg, 0.94 mmol) was dissolved in DCM (10 mL) and diluted with Et 3N (200 μL, 1.41 mmol) and octanoyl chloride (1.5 eq) were added. The mixture was stirred overnight. After evaporation of the solvent, the crude product was dissolved in 1:1 DCM-TFA (4 mL) and triisopropylsilane (320 μL) was added. The reaction mixture was stirred for 1 h, the solvent was evaporated under reduced pressure and co-evaporated with toluene (3×20 mL) to remove TFA traces. The resulting residue was purified by column chromatography (1:4 EtOAc-cyclohexane) to give 40. Yield: 160 mg (75%). R f 0.40 (1:4 EtOAc-cyclohexane). 1 H NMR (300 MHz, CDCl 3 ):δ=6.47(m,2H,NH),4.50(m,1H,CH),3.17(m,2H,CH 2 N), 2.92, 2.66 (m, 2H, SCH 2 ), 2.17(t,2H,CH 2 CO), 1.61-0.78(m, 36H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5 MHz, CDCl 3 ):δ=173.4,169.7(CO),54.1(CH),39.7(CH 2 N), 36.5(CH 2 CO), 31.9-14.0(CH 2 ,CH 2 CH 3 ).HRMS(ESI)calcd for [C 23 H 46 O 2 N 2 SNa] + 437.3172;found 437.3164.

[0141] In a subsequent step, a solution of 32 (20 mg, 0.05 mmol) and 40 (0.10 mmol) in DCM (1.2 mL) was treated with BF 3 -OEt 2 (32 μL, 0.25 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3(3x10mL) and MgSO 4 The mixture was dried over 1000 ml, filtered and concentrated. The residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the target compound 15. Yield: 35 mg (65%). f 0.50 (1:1 EtOAc-cyclohexane). [α] D +3.51 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ): δ = 6.38 (bt, 2H, NHCH 2 ), 5.74(d,1H,J 1,2 =5.9Hz,H-1),5.28(t,1H,J 2,3 =J 3,4 =9.7Hz,H-3),4.87(t,1H,J 4,5 =9.4Hz,H-4),4.86(dd,1H,H-2),4.61(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.43(bt,1H,H-6b),4.27(m,1H,CH),4.15(bdd,1H,H-5),3.12(m,2H,NHCH 2 ), 2.94(dd,1H,J H,H =13.0Hz,J H,H =3.3Hz,SCH 2 ), 2.73(dd,1H,J H,H =15.0Hz,J H,H =10.0Hz,SCH 2 ), 2.18(m,2H,COCH 2 ), 2.01, 1.99, 1.96(3s, 9H, CH 3 CO), 1.61-0.81(m, 36H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ = 173.8, 170.0, 169.7, 169.6169.4 (CO ester), 156.8 (CO carbamate), 72.6 (C-4), 70.3 (C-2), 69.5 (C-3), 67.2 (C-6), 60.2 (C-1), 53.1 (CH), 51.2 (C-5), 39.7 (NHCH 2), 36.7(COCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 36 H 61 N 3 O 10 SNa] + 750.3970. Found 750.3964.

[0142] [Example 16. Synthesis of compound 16]

[0143] Compound 16 was obtained by treating a solution of 15 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 18 mg (quantitative). f 0.5(100:10:1 DCM-MeOH-H 2 O). [α] D +16.91 (in c1.0 5:1 DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ):δ=5.33(s,1H,NH),5.20(d,1H,J 1,2 =5.6Hz,H-1),4.51(t,1H,J 6a,6b =9.5Hz,J 5,6a =8.6Hz,H-6a),4.39(dd,1H,J 5,6b =6.2Hz,H-6b),4.18(dd,1H,J 3,4 =9.5Hz,J 4,5 =5.5Hz,H-4),3.79(m,1H,CH),3.58(m,1H,H-5),3.39(t,1H,J 2,3 =9.3Hz,H-3),3.24(m,1H,H-2),3.08(m,2H,NHCH 2 ),2.86,2.78(dd,2H,SCH 2 ),2.16(t,2H,J H,H =7.0Hz,COCH 2), 1.54-0.79(m,36H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, 5:1 CD 3 OD-CDCl 3 ):δ=174.6,170.7(CO),157.1(CO carbamate),74.0(C-1),73.7(C-3),71.0(C-2),67.0(C-5),62.5(C-6),53.2(C-4),53.1(CH),39.2(NHCH 2 ), 35.6(COCH 2 ), 32.6-13.2(CH 2 ,CH 2 CH 3 ). ESIMS: m / z=602.50[M+H] + Anal.calcd.for C 30 H 55 N 3 O 7 S:C 59.87,H 9.21,N 6.98,S 5.33. Found C 59.64, H 9.07, N 6.70, S 4.99.

[0144] [Example 17. Synthesis of compound 17]

[0145] Compound 17 was obtained by coupling of glycosyl donor 32 with thiol acceptor 41. Acceptor 41 was prepared from commercially available N-Fmoc-S-trityl-L-cysteine ​​by the procedure described below. [ka] To a stirred solution of N-Fmoc-S-trityl-L-cysteine ​​(10 g, 17 mmol) in THF (130 mL) was added HOBt (2.3 g, 17 mmol), DCC (3.5 g, 17 mmol) and dodecylamine (3.1 g, 17 mmol) at ambient temperature. The reaction was stirred for 20 min. The solvent was then removed under reduced pressure and coevaporated with MeOH (3×20 mL) to remove traces of piperidine. The free amine (500 mg, 0.94 mmol) was dissolved in DCM (10 mL) and diluted with Et3 N (200 μL, 1.41 mmol) and dodecyl chloride (1.5 eq) were added. The mixture was stirred overnight. After evaporation of the solvent, the crude product was dissolved in 1:1 DCM-TFA (4 mL) and triisopropylsilane (320 μL) was added. The reaction mixture was stirred for 1 h, the solvent was evaporated under reduced pressure and co-evaporated with toluene (3×20 mL) to remove TFA traces. The resulting residue was purified by column chromatography (1:4 EtOAc-cyclohexane) to give 41. Yield: 230 mg (70%). R f 0.40 (1:4 EtOAc-cyclohexane). 1 H NMR (300 MHz, CDCl 3 ):δ=6.45(m,2H,NH),4.50(m,1H,CH),3.17(m,2H,CH 2 N), 2.94, 2.65 (m, 2H, SCH 2 ), 2.16(t,2H,CH 2 CO), 1.61-0.81(m, 44H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl 3 ):δ=173.4,169.6(CO),54.1(CH),39.7(CH 2 N), 36.5(CH 2 CO), 31.9-14.0(CH 2 ,CH 2 CH 3 ).HRMS(ESI)calcd for[C 27 H 54 O 2 N 2 SNa] + 493.3798;found 493.3793.

[0146] In a subsequent step, a solution of 32 (20 mg, 0.05 mmol) and 41 (0.10 mmol) was added to BF 3 -OEt 2 (32 μL, 0.25 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give the target compound 17. Yield: 27 mg (70%). f 0.50 (1:1 EtOAc-cyclohexane). [α] D +16.24 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ): δ = 6.39 (d, 1H, J NH,CH =9.0Hz,NHCH),6.38(bt,1H,J NH,CH =5.6Hz,NHCH 2 ), 5.73(d,1H,J 1,2 =5.9Hz,H-1),5.28(t,1H,J 2,3 =J 3,4 =10.4Hz,H-3),4.86(t,1H,J 4,5 =9.4Hz,H-4),4.85(dd,1H,H-2),4.61(t,1H,J 5,6a =J 5,6b =8.6Hz,H-6a),4.42(m,1H,CH),4.30(bdd,1H,H-5),4.24(m,1H,H-6b),3.11(m,2H,NHCH 2 ), 2.93(dd,1H,J H,H =15.0Hz,J H,H =3.3Hz,SCH 2 ), 2.72(dd,1H,J H,H =15.0Hz,J H,H =9.9Hz,SCH 2 ), 2.18(m,2H,COCH 2 ), 2.01, 1.99, 1.96(3s, 9H, CH 3 CO), 1.57-0.81(m, 48H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3): δ = 173.8, 170.0, 169.7, 169.4 (CO ester), 156.8 (CO carbamate), 72.6 (C-4), 70.3 (C-2), 69.5 (C-3), 67.3 (C-6), 60.2 (C-1), 53.1 (CH), 51.2 (C-5), 39.7 (NHCH 2 ), 36.7(COCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI)calcd for [C 40 H 69 N 3 O 10 SNa] + 806.4596;found 806.4588.

[0147] [Example 18. Synthesis of compound 18]

[0148] Compound 18 was obtained by treating a solution of 17 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 20 mg (quantitative). f 0.5(70:10:1 DCM-MeOH-H 2 O). [α] D +16.23 (in c1.0 5:1 DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ): δ = 5.20 (d, 1H, J 1,2 =5.7Hz,H-1),4.51(bt,1H,J 5,6a =9.5Hz,J 6a,6b =8.6Hz,H-6a),4.40(dd,1H,J 5,6b =6.3Hz,H-6b),4.18(m,1H,H-5),3.79(m,1H,CH),3.58(dd,1H,J 3,4 =9.5Hz,J 4,5 =5.5Hz,H-4),3.40(t,1H,J 2,3=9.3Hz,H-3),3.22(m,1H,H-2),3.09(m,2H,NHCH 2 ),2.86,2.78(dd,2H,SCH 2 ),2.16(t,2H,J H,H =7.0Hz,COCH 2 ), 1.53-0.79(m,48H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, 4:1 CD 3 OD-CDCl 3 ):δ=174.7,170.7(CO),157.1(CO carbamate),74.1(C-1),73.8(C-3),71.1(C-2),67.1(C-5),62.6(C-6),53.3(C-4),53.2(CH),39.3(NHCH 2 ), 35.8(COCH 2 ), 32.7-13.3(CH 2 ,CH 2 CH 3 ). ESIMS: m / z=658.33[M+H] + Anal.calcd.for C 13 H 16 N 4 O 8 :C 43.82,H 4.53,N 15.73. C 43.89, H 4.60, N 15.57.

[0149] [Example 19. Synthesis of compound 19]

[0150] Compound 19 was obtained by coupling glycosyl donor 46 with thiol acceptor 40. Glycosyl donor 46 was prepared in four steps from 5-azido-3-O-benzyl-5-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (42) according to Scheme 8 below. [ka] Step 1: To a stirred solution of 42 (5.7 g, 17.0 mmol) in dioxane / MeOH (5:1) (230 mL) was added Ph3 P (8.9 g, 34.0 mmol) was added and the reaction mixture was stirred at room temperature for 4 h. 4 OH (32 mL) was added and the mixture was stirred overnight. After that, the solvent was removed under reduced pressure and the residue was purified by column chromatography (EtOAc, 45:5:1→45:5:3 EtOAc-EtOH-H 2 0) to give 5-amino-3-O-benzyl-5-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (43). Yield: 7.1 g (90%). f 0.41(45:5:3 EtOAc-EtOH-H 2 O). [α] D -68.2 (during c0.8 DCM). 1 H NMR (400 MHz, CDCl 3 )δ7.45-7.30(m,5H,CH-arom),5.94(d,1H,J 1,2 =3.8Hz,H-1),4.76(d,1H, 2 J H,H =11.8Hz,OCH 2 Ph),4.64(d,1H,H-2),4.51(d,1H,OCH 2 Ph), 4.03(d, 1H, J 3,4 =3.0Hz,H-3),3.99(dd,1H,J 4,5 =8.4Hz,H-4),3.79(dd,1H,J 6a,6b =10.8Hz,J 5,6a =4.0Hz,H-6a),3.58(dd,1H,J 5,6b =6.0Hz,H-6b),3.29(m,1H,H-5),2.00(bs,1H,OH),1.50,1.34(2s,6H,CMe 2 ). 13 C NMR (100 MHz, CDCl 3 )δ137.2-128.0(C-arom),111.6(CMe 2 ),105.1(C-1),81.7(C-2),81.6(C-3,C-4),71.7(OCH 2 Ph),64.3(C-6),50.9(C-5),26.7,26.2(CMe 2 ). ESIMS: m / z 310.1 [M+H]+ Anal.Calcd for C 16 H 23 NO 5 :C 62.12,H 7.49,N 4.53. C 61.88, H 7.49, N 4.53. Found:C 61.88,H 7.27,N 4.44.

[0151] Step 2: To a stirred solution of amine 43 (7.3 g, 23 mmol) in DCM (162 mL) was added DIPEA (39 mL, 236 mmol) and triphosgene (10.5 g, 35.4 mmol) at 0° C. After 30 min, the solvent was removed under reduced pressure and the residue was purified by column chromatography using EtOAc as eluent to give 5-amino-5-deoxy-1,2-O-isopropylidene-3-O-benzyl-α-D-glucofuranose 5,6-(cyclic carbamate) (44). Yield: 5.4 g (69%). R f 0.84(EtOAc). [α] D -91.7(c0.96 CHCl 3 middle). 1 H NMR (400 MHz, CDCl 3 )δ7.50-7.30(m,5H,CH-arom),5.95(d,1H,J 1,2 =3.8Hz,H-1),5.38(bs,1H,NH),4.74(d,1H, 2 J H,H =11.8Hz,OCH 2 Ph),4.68(d,1H,H-2),4.51(d,1H,OCH 2 Ph),4.51-4.46(m,1H,H-6a),4.43(dd,1H,J 6b,6a =8.8Hz,J 5,6b =4.8Hz,H-6b),4.20(dd,1H,J 4,5 =7.8Hz,J 3,4 =3.4Hz,H-4),4.12-4.05(m,1H,H-5),4.02(d,1H,H-3),1.52,1.35(2s,6H,CMe 2 ). 13 C NMR (100 MHz, CDCl 3)δ160.0(CO),137.1-128.0(C-arom),112.2(CMe 2 ),105.5(C-1),82.0(C-2),81.6(C-4),81.3(C-3),71.8(OCH 2 Ph),68.1(C-6),50.8(C-5),26.9,26.3(CMe 2 ). ESIMS: m / z 358.1 [M+Na] + Anal.Calcd for C 17 H 21 NO 6 :C 60.89,H 6.31,N 4.18. Found C 60.93, H 6.24, N 4.09.

[0152] Step 3: 90% TFA-H 2 A solution of 44 (2.1 g, 6.2 mmol) in 2H2O (9.8 mL) was stirred at room temperature for 30 min. The solvent was removed under reduced pressure, coevaporated with water several times, treated with NaOH 0.1N to pH 8, and concentrated. The resulting residue was purified by column chromatography using EtOAc as eluent, and the product was lyophilized from aqueous solution to give 3-O-benzyl-5N,6O-oxomethylidene nojirimycin (45). Yield: 1.6 g (90%). R f 0.60(EtOAc). [α] D -2.7(c1.0 H 2 during O). 1 H NMR (400MHz, D 2 O)δ7.50-7.30(m,5H,CH-arom),5.33(d,1H,J 1,2 =4.0Hz,H-1),4.84(d,1H, 2 J H,H =10.8Hz,OCH 2 Ph), 4.80(d, 1H, OCH 2 Ph), 4.57(t, 1H, J 6a,6b =J 5,6a =8.8Hz,H-6a),4.25(dd,1H,J 5,6b =6.8Hz,H-6b),3.98-3.90(m,1H,H-5),3.70(t,1H,J 2,3 =J 3,4=9.4Hz,H-3),3.63(dd,1H,H-2),3.56(t,1H,J 4,5 =9.4Hz,H-4). 13 C NMR (100MHz, D 2 O)δ157.6(CO),137.6-128.4(C-arom),80.9(C-3),75.3(OCH 2 Ph),74.6(C-1),73.3(C-4),71.1(C-2),67.6(C-6),53.2(C-5).ESIMS:m / z 318.1[M+Na] + Anal.Calcd for C 14 H 17 NO 6 :C 56.94, H 5.80, N 4.74. C 56.75, H 5.80, N 4.74. Found: C 56.75, H 5.63, N 4.57.

[0153] Step 4: To a stirred solution of 45 (1.6 g, 5.4 mmol) in pyridine (7 mL) was added Ac 2 O (7 mL, 74 mmol) was added and the mixture was stirred at room temperature overnight. The reaction was added dropwise to ice water (100 mL), extracted with DCM (3x20 mL), and the organic phase was washed with HCl 1M (3x20 mL), brine (20 mL), and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The residue was purified by column chromatography eluting with 1:1 EtOAc-cyclohexane to give (1R)-1,4-di-O-acetyl-3-O-benzyl-5N,6O-oxomethylidene nojirimycin (46). Yield: 2 g (87%). f 0.42 (1:1 EtOAc-cyclohexane). [α] D +13.5 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 )δ7.30-7.16(m,5H,CH-arom),6.62(d,1H,J 1,2 =3.8Hz,H-1),5.00(dd,1H,J 2,3 =10.0Hz,H-2),4.86(t,1H,J 3,4 =J 4,5=9.4Hz),4.62(d,2H, 2 J H,H =10.8Hz,OCH 2 Ph), 4.32(dd, 1H, J 6a,6b =J 5,6a =8.2Hz,H-6a),4.21(dd,1H,J 5,6b =6.8Hz,H-6b),3.89(m,2H,H-3,H-5),2.99,1.93,1.91(3s,3H,COOCH 3 ). 13 C NMR (75.5 MHz, CDCl 3 ) δ170.0, 169.2, 168.5 (CO ester), 154.3 (CO carbamate), 137.7-127.4 (C-arom), 76.7 (C-3), 75.5 (OCH 2 Ph),73.8(C-4),72.7(C-1),71.0(C-2),67.2(C-6),53.2(C-5). HRMS(ESI) calcd for [C 20 H 23 NO 9 Na] + 444.1276;found 444.1261.

[0154] In a subsequent step, a solution of 46 (150 mg, 0.35 mmol) and 40 (0.53 mmol) was treated with BF under Ar atmosphere at 0 °C. 3 -OEt 2 (215 μL, 1.78 mmol) was added. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give the target compound 19. Yield: 200 mg (68%). f 0.65 (1:1 EtOAc-cyclohexane). [α] D +31.50 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ7.28-7.16(m,5H,CH-arom),6.64(d,1H,J NH,CH=8.5Hz,NHCH),6.54(bt,1H,J NH,CH =5.6Hz,NHCH 2 ),5.72(d,1H,J 1,2 =5.8Hz,H-1),4.85(t,1H,J 2,3 =J 3,4 =7.5Hz,H-3),4.83(t,1H,J 4,5 =9.5Hz,H-4),4.67(d,1H, 2 J H,H =11.5Hz,OCH 2 Ph),4.56(d,1H, 2 J H,H =11.8Hz,OCH 2 Ph),4.54(bdd,1H,H-2),4.46(m,1H,CH),4.28(t,1H,J 6a,6b =J 5,6a =8.6Hz,H-6a),4.19(m,1H,H-5),3.75(t,1H,H-6b),3.11(m,2H,NHCH 2 ),2.95(dd,1H,J H,H =15.0Hz,J H,H =3.3Hz,SCH 2 ),2.73(dd,1H,J H,H =15.0Hz,J H,H =9.9Hz,SCH 2 ),2.18(m,2H,COCH 2 ),1.99,1.91(2s,6H,CH 3 CO),1.59-0.80(m,48H,CH 2 ,CH 2 CH 3 )。 13 C NMR(125.7MHz,CDCl 3 ):δ=174.0,170.1,169.8,169.6(CO),157.0(COカルバメート),137.7-127.4(C-arom),77.4(CH 2 Ph),75.6(C-4),74.1(C-2),72.4(C-3),67.6(C-6),60.1(C-1),53.4(CH),51.8(C-5),39.7(NHCH 2 ),36.6(COCH 2 ),31.9-14.1(CH3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 45 H 74 N 3 O 9 SNa] + 832.5140;found 832.5140.

[0155] [Example 20. Synthesis of compound 20]

[0156] Compound 20 was obtained by treating a solution of 19 in MeOH (3.6 mL) with 1 M NaOMe in MeOH (25 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration and evaporation to dryness. Yield: 54 mg (quantitative). f 0.5 (2:1 EtOAc-cyclohexane). [α] D +43.06 (during c1.0 DCM). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ):δ=7.33-7.14(m,5H,CH-arom),5.20(d,1H,J 1,2 =5.7Hz,H-1),4.76(d,1H, 2 J H,H =11.2Hz,OCH 2 Ph), 4.51(t, 1H, J 6a,6b =9.5Hz,J 5,6a =8.5Hz,H-6a),4.40dd,1H,J 5,6b =6.4Hz,H-6b),4.16(dd,1H,J 3,4 =9.1Hz,J 4,5 =5.9Hz,H-4),3.81(m,1H,H-5),3.74(m,1H,CH),3.37(m,2H,H-2,H-3),3.09(m,2H,NHCH 2 ), 2.87, 2.80(dd,2H,SCH 2 ),2.16(t,2H,J H,H =7.0Hz,COCH 2 ), 1.53-0.79(m,48H,CH 2 ,CH2 CH 3 ). 13 C NMR (125.7MHz, 4:1 CD 3 OD-CDCl 3 ): δ = 174.7, 170.7 (CO), 157.0 (CO carbamate), 138.6-127.3 (C-arom), 82.4 (CH 2 Ph),75.3(C-4),73.9(C-2),71.3(C-3),67.1(C-6),62.8(C-1),53.5(CH),53.2(C-5),39.3(NHCH 2 ), 35.7(COCH 2 ), 32.6-13.3(CH 2 ,CH 2 CH 3 ). HRMS(ESI)calcd for [C 41 H 69 N 3 O 7 SNa] + 770.4748;found 770.4741.

[0157] [Example 21. Synthesis of compound 21]

[0158] Compound 21 was obtained by coupling of glycosyl donor 32 with thiol acceptor 47, which was prepared from commercially available N-Fmoc-S-trityl-L-cysteine ​​as described below. [ka] To a stirred solution of N-Fmoc-S-trityl-L-cysteine ​​(10 g, 17 mmol) in THF (130 mL) was added HOBt (2.3 g, 17 mmol), DCC (3.5 g, 17 mmol) and dodecylamine (3.1 g, 17 mmol) at room temperature. The mixture was stirred overnight, filtered and concentrated. The crude mixture was dissolved in THF (132 mL) and piperidine (20 mL) was added. The reaction mixture was stirred for 20 min. The solvent was then removed under reduced pressure and co-evaporated with MeOH (3×20 mL) to remove traces of piperidine. The free amine (500 mg, 0.94 mmol) was dissolved in DCM (10 mL) and diluted with Et 3 N (200 μL, 1.41 mmol) and tetradecanoyl chloride (1.5 eq) were added. The mixture was stirred overnight. After evaporation of the solvent, the crude product was dissolved in 1:1 DCM-TFA (4 mL) and triisopropylsilane (320 μL) was added. The reaction mixture was stirred for 1 h, the solvent was evaporated under reduced pressure and co-evaporated with toluene (3x20 mL) to remove TFA traces. The resulting residue was purified by column chromatography (1:4 EtOAc-cyclohexane) to give 47. Yield: 250 mg (53%, 2 steps). R f 0.50 (1:4 EtOAc-cyclohexane). [α] D -18.96 (c 1.0 in DCM). Column chromatography 1:4 EtOAc-cyclohexane. Yield: 250 mg (53%, 2 steps). R f 0.50 (1:4 EtOAc-cyclohexane). [α] D -18.96 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 ):δ=6.46(m,2H,NH),4.50(m,1H,CH),3.17(m,2H,CH 2 N), 2.94, 2.65 (m, 2H, SCH 2 ), 2.17(t,2H,CH 2 CO), 1.57-0.81(m, 48H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl 3):δ=173.5,169.7(CO),54.1(CH),39.7(CH 2 N), 36.5(CH 2 CO), 31.9-14.0(CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 28 H 59 O 5 N.S. + 521.4108;found 521.4107.

[0159] In a subsequent step, a solution of 32 (50 mg, 0.13 mmol) and 47 (0.19 mmol) was added to BF 3 -OEt 2 (80 μL, 0.65 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the target compound 21. Yield: 92 mg (76%). f 0.60 (1:1 EtOAc-cyclohexane). [α] D +15.40 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ): δ = 6.42 (bt, 2H, NHCH 2 ), 5.72(d,1H,J 1,2 =5.9Hz,H-1),5.27(t,1H,J 2,3 =J 3,4 =9.8Hz,H-3),4.86(t,1H,J 4,5 =9.3Hz,H-4),4.85(dd,1H,H-2),4.59(t,1H,J 6a,6b =J 5,6a =8.5Hz,H-6a),4.41(m,1H,CH),4.28(bdd,1H,H-5),4.23(bt,1H,H-6b),3.10(m,2H,NHCH 2 ), 2.92(dd,1H,J H,H =13.0Hz,J H,H=3.3Hz,SCH 2 ), 2.71(dd,1H,J H,H =15.0Hz,J H,H =10.0Hz,SCH 2 ), 2.17(m,2H,COCH 2 ), 2.00, 1.98, 1.95(3s, 9H, CH 3 CO), 1.58-0.79(m, 46H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ = 173.8, 170.1, 169.7, 169.6, 169.4 (CO ester), 156.8 (CO carbamate), 72.6 (C-4), 70.2 (C-2), 69.5 (C-3), 67.2 (C-6), 60.0 (C-1), 53.1 (CH), 51.2 (C-5), 47.0 (NHCH 2 ), 39.7(COCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 36 H 61 N 3 O 10 SNa] + 750.3970;found 750.3964.

[0160] [Synthesis of compound 22]

[0161] Compound 22 was obtained by treating a solution of 21 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 80 mg (quantitative). f 0.5(100:10:1 DCM-MeOH-H 2 O). [α] D +16.23 (in c1.0 1:1 DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl3 ):δ=d,1H,J 1,2 =5.7Hz,H-1),4.51(bt,1H,J 6a,6b =9.5Hz,J 5,6a =8.6Hz,H-6a),4.40(dd,1H,J 5,6b =6.3Hz,H-6b),4.18(m,1H,H-5),3.79(m,1H,CH),3.58(dd,1H,J 3,4 =9.5Hz,J 4,5 =5.5Hz,H-4).5Hz,H-4),3.40(t,1H,J 2,3 =9.3Hz,H-3),3.22(m,1H,H-2),3.09(m,2H,NHCH 2 ),2.86,2.78(dd,2H,SCH 2 ),2.16(t,2H,J H,H =7.0Hz,COCH 2 ),1.53-0.79(m,48H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7 MHz, 4:1 CD 3 OD-CDCl 3 ): δ=174.7,170.7(CO),157.1(COカルバメート),74.1(C-1),73.8(C-3),7 1.1(C-2),67.1(C-5),62.6(C-6),53.3(C-4),53.2(CH),39.3(NHCH 2 ),35.8(COCH 2 ),32.7-13.3(CH 2 ,CH 2 CH 3 ). ESIMS: m / z = 686.60 [M + H] + . Anal.calcd.for C 36 H 67 N 7 O 7 S: C63.03, H 9.84, N 6.13, S 4.67. Found C,62.85,H 9.52,N 5.83,S 4.30.

[0162] [Example 23. Synthesis of compound 23]

[0163] Compound 23 was obtained by coupling of glycosyl donor 32 with thiol acceptor 48. Acceptor 48 was prepared from commercially available N-Fmoc-S-trityl-L-cysteine ​​by the procedure described below. [ka] To a stirred solution of N-Fmoc-S-trityl-L-cysteine ​​(10 g, 17 mmol) in THF (130 mL) was added HOBt (2.3 g, 17 mmol), DCC (3.5 g, 17 mmol) and dodecylamine (3.1 g, 17 mmol) at room temperature. The mixture was stirred overnight, filtered and concentrated. The crude mixture was dissolved in THF (132 mL) and piperidine (20 mL) was added. The reaction mixture was stirred for 20 min. The solvent was then removed under reduced pressure and co-evaporated with MeOH (3×20 mL) to remove traces of piperidine. The free amine (500 mg, 0.94 mmol) was dissolved in DCM (10 mL) and diluted with Et 3 N (200 μL, 1.41 mmol) and hydrocinnamoyl chloride (1.5 eq) were added. The mixture was stirred overnight. After evaporation of the solvent, the crude product was dissolved in 1:1 DCM-TFA (4 mL) and triisopropylsilane (320 μL) was added. The reaction mixture was stirred for 1 h, the solvent was evaporated under reduced pressure and co-evaporated with toluene (3×20 mL) to remove TFA traces. The resulting residue was purified by column chromatography (1:4 EtOAc-cyclohexane) to give 48. Yield: 114 mg (72%). R f 0.40 (1:4 EtOAc-cyclohexane). 1 H NMR (300 MHz, CDCl 3 ):δ=7.24-7.11(m,5H,CH-arom),6.33.(m,2H,NH),4.46(m,1H,CH),3.12(m,2H,CH 2 N), 2.90, 2.49 (m, 2H, SCH 2 ), 2.17(m,2H,CH 2 CO), 1.47-0.78(m, 25H, CH 2 ,CH 2 CH 3 ).13 C NMR (75.5MHz, CDCl 3 ):δ=172.2,169.4(CO),140.3-126.4(C-arom),54.1(CH),39.7(CH 2 N), 36.5(CH 2 CO), 31.9-14.0(CH 2 ,CH 2 CH 3 ). HRMS(ESI)calcd for [C 24 H 40 O 2 N 2 SNa] + 443.2703;found 443.2703.

[0164] In a subsequent step, a solution of 32 (50 mg, 0.13 mmol) and 48 (0.19 mmol) was added to BF 3 -OEt 2 (80 μL, 0.65 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The resulting acetylated compound was dissolved in MeOH (1.3 mL) and treated with 1M NaOMe in MeOH (20 μL), then neutralized with Amberlite® IR120 hydrogen foam, filtered, and evaporated to dryness. The resulting residue was purified by column chromatography (100:10:1 DCM-MeOH-H 2 O) to obtain the target compound 23. Yield: 22 mg (quantitative). f 0.5(100:10:1 DCM-MeOH-H 2 O). [α] D +28.98 (in c1.0 1:5 DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ):δ=7.12(m,5H,CH-arom),5.17(d,1H,J 1,2 =5.6Hz,H-1),4.49(t,1H,J 6a,6b =9.5Hz,J 5,6a=8.6Hz,H-6a),4.38(dd,1H,J 5,6b =6.2Hz,H-6b),4.17(dd,1H,J 3,4 =9.5Hz,J 4,5 =5.5Hz,H-4),3.77(m,1H,CH),3.57(m,1H,H-5),3.39(t,1H,J 2,3 =9.3Hz,H-3),3.22(m,1H,H-2),3.05(m,2H,NHCH 2 ),2.83,2.82,2.74(dd,4H,SCH 2 ,CH 2 Ph),2.47(t,2H,J H,H =7.0Hz,COCH 2 ),1.40-0.79(m,23H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7 MHz, 5:1 CD 3 OD-CDCl 3 ): δ=173.6,170.6(CO),157.1(COカルバメート),140.6-125.9(C-arom),74.0(C-1),7 3.8(C-3),71.1(C-2),67.1(C-5),62.6(C-6),53.3(C-4),53.2(CH),39.3(NHCH 2 ),37.4(COCH 2 ),32.6-13.2(CH 2 ,CH 2 CH 3 ). ESIMS: m / z=608.44[M+H] + . Anal.calcd.for C 31 H 49 N 3 O 7 S: C 61.26, H 8.13, N 6.91, S 5.27. Found C60.97, H 7.88, N 6.71, S 4.96.

[0165] [Example 24. Synthesis of compound 24]

[0166] Compound 24 was obtained by coupling of glycosyl donor 32 with thiol acceptor 49. Acceptor 49 was prepared from commercially available N-Fmoc-S-trityl-L-cysteine ​​by the procedure described below. [ka] To a stirred solution of N-Fmoc-S-trityl-L-cysteine ​​(10 g, 17 mmol) in THF (130 mL) was added HOBt (2.3 g, 17 mmol), DCC (3.5 g, 17 mmol) and dodecylamine (3.1 g, 17 mmol) at rt. The mixture was stirred overnight, filtered and concentrated. The crude mixture was dissolved in THF (132 mL) and piperidine (20 mL) was added. The reaction mixture was stirred for 20 min. The solvent was then removed under reduced pressure and co-evaporated with MeOH (3×20 mL) to remove traces of piperidine. The free amine (500 mg, 0.94 mmol) was dissolved in DCM (10 mL) and diluted with Et 3 N (200 μL, 1.41 mmol) and 1-octanesulfonyl chloride (1.5 eq) were added. The mixture was stirred overnight. After evaporation of the solvent, the crude product was dissolved in 1:1 DCM-TFA (4 mL) and triisopropylsilane (320 μL) was added. The reaction mixture was stirred for 1 h, the solvent was evaporated under reduced pressure and co-evaporated with toluene (3x20 mL) to remove TFA traces. The resulting residue was purified by column chromatography (1:4 EtOAc-cyclohexane) to give 49. Yield: 155 mg (80%). R f 0.40 (1:4 EtOAc-cyclohexane). 1 H NMR (300 MHz, CDCl 3 ):δ=6.43(m,2H,NH),3.98(m,1H,CH),3.10(m,2H,CH 2 S), 3.21(m, 2H, CH 2 N), 2.97, 2.68(m, 2H, SCH 2 ), 1.91-0.81(m,38H,CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl3 ):δ=168.8(CO),58.1(CH),53.7(CH 2 S), 40.0(CH 2 N), 31.9-14.0(CH 2 ,CH 2 CH 3 ). HRMS(ESI)calcd for [C 23 H 49 O 3 N 2 S 2 Na] + 465.3179;found 465.3174.

[0167] In a subsequent step, a solution of 32 (50 mg, 0.13 mmol) and 49 (0.19 mmol) was added to BF 3 -OEt 2 (80 μL, 0.65 mmol) was added under Ar atmosphere at 0° C. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give the target compound 24. Yield: 70 mg (55%). f 0.50 (1:1 EtOAc-cyclohexane). [α] D +14.94 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ): δ = 6.55 (bt, 1H, J NH,CH =5.6Hz,NHCH 2 ), 5.71(d,1H,J 1,2 =5.9Hz,H-1),5.27(t,1H,J 2,3 =J 3,4 =10.4Hz,H-3),4.89(t,1H,J 4,5 =9.4Hz,H-4),4.86(dd,1H,H-2),4.55(t,1H,J 6a,6b =J 5,6a =8.6Hz,H-6a),4.35(m,1H,H-6b),4.23(bdd,1H,H-5),3.71(m,1H,CH),3.15(m,2H,NHCH 2), 2.93-2.73(m,4H,SCH 2 ), 2.02, 1.99, 1.97(3s, 9H, CH 3 CO), 1.72-0.81(m, 38H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ = 170.1, 169.8, 169.2, 169.1 (CO ester), 156.9 (CO carbamate), 72.5 (C-4), 70.2 (C-2), 69.4 (C-3), 67.4 (C-6), 61.0 (C-1), 57.3 (CH), 53.7 (C-5), 51.5 (NHCH 2 ), 40.0(COCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI)calcd for [C 36 H 63 N 3 O 11 S 2 Na] + 800.3796;found 800.3790.

[0168] [Example 25. Synthesis of compound 25]

[0169] Compound 25 was obtained by treating a solution of 24 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), neutralizing with Amberlite® IR120 hydrogen foam, filtering, and evaporating to dryness. Yield: 50 mg (quantitative). f 0.5(100:10:1 DCM-MeOH-H 2 O). [α] D +34.60 (c1.0 in DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ): δ = 5.31 (d, 1H, J 1,2 =5.5Hz,H-1),4.59(bt,1H,J 6a,6b =9.5Hz,J 5,6a=8.6Hz,H-6a),4.26(dd,1H,J 5,6b =5.9Hz,H-6b),3.96(m,1H,H-5),3.92(m,1H,CH),3.67(dd,1H,J 3,4 =9.8Hz,J 4,5 =5.6Hz,H-4),3.49(t,1H,J 2,3 =9.2Hz,H-3),3.30(m,1H,H-2),3.20(m,2H,NHCH 2 ), 3.00, 2.88(m, 2H, SCH 2 ), 1.75-0.88(m,38H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, 5:1 CD 33 OD-CDCl 3 ):δ=170.7(CO),157.2(CO carbamate),74.0(C-1),73.7(C-3),71.0(C-2),67.1(C-5),62.6(C-6),56.6(C-4),53.3(CH),53.1(NHCH 2 ), 39.4-13.3(CH 2 ,CH 2 CH 3 ). ESIMS: m / z=652.46[M+H] + Anal.calcd.for C 30 H 57 N 3 O 8 S 2 :C 55.27,H 8.81,N 6.45,S 9.84. Found C 54.98, H 8.63, N 6.21, S 9.55.

[0170] [Example 26. Synthesis of compound 26]

[0171] The synthesis of compound 26 involves a first bond between a glycosyl donor 33 and an acceptor 36 to give intermediate 50. [ka] A solution of 33 (20 mg, 0.05 mmol) in dry DCM (1.2 mL) was treated with L-serine derivative 36 (0.10 mmol) and BF at 0 °C under Ar atmosphere. 3 -OEt 2 (32 μL, 0.25 mmol) was added. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:2 EtOAc-cyclohexane) to give 50. Yield: 106 mg (60%). f 0.60 (2:1 EtOAc-cyclohexane). [α] D +33.71 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 ):δ=7.95-7.28(m,12H,CH-arom),6.21(bt,1H,J NH,CH2 =5.6Hz,NHCH 2 ),5.65(d.1H,J NH,CH = 7.8Hz, NH Fmoc), 5.51(d, 1H, J 1,2 =4.0Hz,H-1),5.42(bt,1H,J 3,4 =2.6Hz,J 4,5 =2.2Hz,H-4),5.28(dd,1H,J 2,3 =10.9Hz,H-3),5.13(dd,1H,H-2),4.07(m,4H,H-6a,OCH 2 CH,CH 2 Fmoc),4.23(m,2H,H-5,CHFmoc),4.00(dd,1H,J 5,6a =J 5,6b =8.6Hz,J 6a,6b =5.9Hz,H-6b),3.79(d,2H,OCH 2 CH), 3.25(m, 2H, NHCH 2 ), 2.19, 2.10, 2.01 (3s, 9H, CH 3 CO), 1.73-0.89(m, 25H, CH 2 ,CH 2 CH 3 ). 13 C NMR (75.5MHz, CDCl3 ): δ = 170.2, 169.8 (CO), 155.9 (CO carbamate), 143.6-120.0 (C-arom), 80.1 (C-1), 69.2 (OCH 2 CH), 67.8(C-4, C-3), 67.2(C-2, CH 2 Fmoc), 63.0 (C-6), 54.4 (OCH 2 CH),50.6(CH Fmoc),47.0(C-5),39.8(NHCH 2 ), 31.9-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ).ESIMS: m / z=830.38[M+Na] + HRMS(ESI)calcdfor [C 43 H 57 O 12 N 3 Na] + 830.3834;found 830.3825.

[0172] In a subsequent step, piperidine (131 μL, 1 mL / mmol) was added to a stirred solution of 50 (100 mg, 0.131 mmol) in DMF (1.5 mL). After 1 h, the mixture was concentrated and the crude product was dissolved in DMF (1.8 mL) and treated with dodecanoyl chloride (47 μL, 0.196 mmol) and Et 3 N (37 μL, 0.262 mmol) was added. The mixture was stirred for 16 h and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give the target compound 26. Yield: 65 mg (85%). R f 0.30 (1:1 EtOAc-cyclohexane). [α] D +40.83 (during c1.0 DCM). 1 H NMR (300 MHz, CDCl 3 ): δ = 6.39 (d, 1H, J NH,CH =8.2Hz,NHCH),6.34(bt,1H,J NH,CH =5.6Hz,NHCH 2 ), 5.51(d,1H,J 1,2=4.0Hz,H-1),5.42(bt,1H,J 3,4 =2.6Hz,J 4,5 =2.2Hz,H-4),5.28(dd,1H,J 2,3 =10.7Hz,H-3),5.13(dd,1H,H-2),4.61(m,1H,OCH 2 CH),4.46(t,1H,J 5,6a =J 5,6b =8.8Hz,H-6a),4.29(m,1H,H-5),4.02(dd,1H,J 5,6b =6.0Hz,H-6b),2.00(d,2H, 2 J H,H =6.6Hz,OCH 2 CH),3.49(m,2H,COCH 2 ),3.25(m,2H,NHCH 2 ),2.19,2.12,2.01(3s,9H,CH 3 CO),1.64-0.89(m,48H,CH 2 ,CH 2 CH 3 )。 13 C NMR(75.5MHz,CDCl 3 ):δ=173.4,170.2,169.8,169.1(CO),156.1(COカルバメート),80.1(C-1),68.8(C-4),67.8(C-3,OCH 2 CH),67.2(C-2),63.1(C-6),52.3(OCH 2 CH),50.6(C-5),49.1(COCH 2 ),39.8(NHCH 2 ),36.5-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ).ESIMS:m / z=790.48[M+Na] + 。HRMS(ESI) calcd for [C 40 H 69 O 11 N 3 Na] + 790.4824;found 790.4816。

[0173] [Example 27. Synthesis of compound 27]

[0174] Compound 27 was obtained by treating a solution of 26 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 33 mg (quantitative). f 0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +15.61 (c1.0 in DCM-MeOH). 1 H NMR (500MHz, 1:1 MeOD-CDCl 3 ): δ = 5.13 (d, 1H, J 1,2 =4.2Hz,H-1),4.55(dd,1H,J 4,5 =7.5Hz,J 4,5 =5.9Hz,H-4),4.43(m,1H,OCH 2 CH), 3.97(m, 2H, OCH 2 CH),3.82(m,2H,H-2,H-6a),3.73(m,2H,H-3,H-6b),3.65(m,1H,H-5),3.19(m,2H,NHCH 2 ), 2.24(m,2H,COCH 2 ), 1.87-0.88(m,48H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, 1:1 CD 3 OD-CDCl 3 ): δ = 174.6, 170.3 (CO ester), 157.7 (CO carbamate), 82.5 (C-1), 70.0 (C-2), 68.7 (C-3), 67.8 (C-6), 67.7 (C-5), 63.7 (OCH 2 CH), 52.8(C-4), 52.6(OCH 2 CH), 39.5(NHCH 2 ), 35.8(COCH 2 ), 31.7-13.5(CH 2 ,CH 2 CH 3 ).ESIMS: m / z=664.45[M+Na] +HRMS(ESI) calcd for [C 34 H 63 O 8 N 3 Na] + 664.4507;found 664.4503.

[0175] [Example 28. Synthesis of compound 28]

[0176] A solution of 33 (20 mg, 0.05 mmol) and 40 (0.10 mmol) was added to BF at 0 °C under Ar atmosphere. 3 -OEt 2 (32 μL, 0.25 mmol) was added. After 1 h, the mixture was diluted with DCM (5 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography (1:1 EtOAc-cyclohexane) to give the target compound 28. Yield: 27 mg (70%). f 0.40 (1:1 EtOAc-cyclohexane). [α] D +31.24 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ=6.39(m,2H,NH),5.86(d,1H,J 1,2 =3.9Hz,H-1),5.35(bs,1H,H-4),5.08(bd,2H,H-2,H-3),4.60(dd,1H,J 5,6a =J 5,6b =8.6Hz,H-6a),4.57(m,1H,H-5),4.42(m,1H,CH),3.98(dd,1H,J 5,6b =5.1Hz,H-6b),3.12(m,2H,NHCH 2 ), 2.95(dd,1H,J H,H =15.0Hz,J H,H =1.8Hz,SCH 2 ), 2.68(dd,1H,J H,H =15.0Hz,J H,H =10.4Hz,SCH 2 ), 2.18(m,2H,CH 2CO), 2.10, 2.02, 1.93 (3s, 9H, CH 3 CO), 1.58-0.81(m, 48H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3 ): δ = 173.8, 170.1, 169.9, 169.7 (CO ester), 157.0 (CO carbamate), 68.5 (C-1), 67.4 (C-4), 67.2 (C-3), 63.5 (C-2), 60.6 (C-6), 52.9 (CH), 50.3 (C-5), 39.7 (NHCH 2 ), 36.7-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 40 H 69 O 10 N 3 SNa] + 806.4596;found 806.4590.

[0177] [Example 29. Synthesis of compound 29]

[0178] Compound 29 was obtained by treating a solution of 28 in MeOH (2.6 mL) with 1 M NaOMe in MeOH (42 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation, and lyophilization. Yield: 22 mg (quantitative). f 0.6(70:10:1 DCM-MeOH-H 2 O). [α] D +20.12 (c1.0 in DCM:MeOH). 1 H NMR (500MHz, 5:1 CD 3 OD-CDCl 3 ): δ = 5.30 (d, 1H, J 1,2 =5.8Hz,H-1),4.39(m,3H,H-6a,H-4,H-2),4.08(m,1H,CH),3.98(m,1H,J 6a,6b =9.6Hz,J 5,6b=5.7Hz,H-6b),3.75(bt,1H,H-3),3.54(dd,1H,J 5,6 =10.0Hz,J 4,5 =2.6Hz H-5), 3.09(m, 2H, NHCH 2 ), 2.84, 2.75(dd,2H,SCH 2 ), 2.16(t,2H,COCH 2 ), 1.53-0.79(m,48H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, 5:1 CD 3 OD-CDCl 3 ):δ=174.7,170.7(CO),157.8(CO carbamate),70.7(C-1),68.4(C-2),67.1(C-3),63.6(C-5),62.8(C-6),53.2(CH),52.7(C-4),39.4(NHCH 2 ), 35.9(COCH 2 ), 31.7-13.5(CH 2 ,CH 2 CH 3 ).ESIMS: m / z=658.34[M+H] + Anal.calcd.forC 34 H 63 N 3 SO 7 :C 62.07, H 9.65, N 6.39, S 4.87. Found C 61.88, H 9.61, N 6.19, S 4.65.

[0179] [Example 30. Synthesis of compound 30]

[0180] The synthesis of compound 30 involves first coupling of a glycosyl donor 46 with an acceptor 36 to give intermediate 51. [ka] A solution of 46 (200 mg, 0.47 mmol) and 36 (0.71 mmol) was treated with BF at 0 °C under Ar atmosphere. 3 -OEt 2(286 μL, 2.37 mmol) was added. After 1 h, the mixture was diluted with DCM (10 mL) and saturated NaHCO 3 (3x10mL) and MgSO 4 The mixture was dried at 40° C., filtered and concentrated. The resulting residue was purified by column chromatography eluting with 1:2 EtOAc-cyclohexane. Yield: 250 mg (65%). f 0.60 (1:1 EtOAc-cyclohexane) to give 51. [α] D +30.53 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ=7.60-7.13(m,12H,CH-arom),6.20(t,1H,J NH,CH2 =5.6Hz,NHCH 2 ), 5.73(d.1H,J NH,CH =5.8Hz,NHFmoc),4.80(m,2H,H-1,H-3),4.62(d,1H, 2 J H,H =11.5Hz,OCH 2 Ph), 4.52(d, 1H, 2 J H,H =11.8Hz,OCH 2 Ph), 4.33(dd, 3H, J 6a,6b =J 5,6a =8.2Hz,H-6a,OCH 2 ,CH 2 Fmoc), 4.20(t,1H,J 3,4 =J 4,5 =8.6Hz,H-4),4.15bt,1H,H-2),3.85(m,2H,H-6b,CH),3.40(m,1H,H-5),3.16(m,2H,NHCH 2 ), 1.97, 1.85(2s, 6H, CH 3 CO), 1.63-0.80(m, 25H, CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3): δ = 170.0, 169.8, 168.7 (CO), 156.9 (CO carbamate), 143.7-120.0 (C-arom), 79.9 (C-1), 76.8 (OCH 2 CH),75.5(C-4),74.1(C-2),72.4(C-3),69.8(C-6),67.4(CH 2 Fmoc), 52.3(OCH 2 CH),49.4(CHFmoc),47.1(C-5),839.8(NHCH 2 ), 33.7-14.1(CH 3 CO,CH 2 ,CH 2 CH 3 ). HRMS(ESI) calcd for [C 48 H 61 O 11 N 3 Na] + 878.4198;found 878.4191.

[0181] In a subsequent step, to a solution of 51 (418 mg, 0.488 mmol) in THF (4.8 mL) piperidine (964 μL, 20% vol) was added and the reaction was stirred for 15 min. The solvent was then evaporated and coevaporated with MeOH to remove traces of piperidine. The crude product was dissolved in DCM (4.8 mL) and washed with dodecanoyl chloride (170 μL, 0.732 mmol) and Et 3 N (137 μL, 0.976 mmol) was added. The mixture was stirred for 16 h and concentrated. The resulting residue was purified by column chromatography 1:1 EtOAc-cyclohexane to give the target compound 30. Yield: 200 mg (50%, 2 steps). f 0.50 (1:1 EtOAc-cyclohexane). [α] D +22.40 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ=7.27-7.15(m,5H,CH-arom),6.49(d,1H,J NH,CH =8.0Hz,NHCH),6.33(t,1H,J NH,CH =5.7Hz,NHCH 2 ),5.34(d,1H,J1,2 =3.9Hz,H-1),4.82(t,1H,J 4,5 =9.5Hz,H-4),4.80(dd,1H,J 2,3 =10.0Hz,H-2),4.65(d,1H, 2 J H,H =11.6Hz,OCH 2 Ph),4.57(d,1H, 2 J H,H =11.7Hz,OCH 2 Ph)、4.53(m,1H,OCH 2 CH)、4.37(t,1H,J 5,6a =J 6a,6b =8.9Hz,H-6a)、4.21(bdd,1H,H-6b)、3.86(m,1H,H-3)、3.71(m,1H,H-5)、3.41(m,2H,OCH 2 CH),3.15(m,2H,NHCH 2 ),2.16(t,2H,COCH 2 ),2.00,1.90(2s,6H,CH 3 CO),1.64-0.80(m,48H,CH 2 ,CH 2 CH 3 )。 13 C NMR(125.7MHz,CDCl 3 ):δ=174.3,170.8,170.5,169.9(CO),157.2(COカルバメート),138.5-128.1(C-arom),80.5(C-1),76.2(C-4),74.9(C-2),73.2(C-3),69.9(OCH 2 CH),68.2(C-6),53.5(OCH 2 CH),53.0(C-5),40.4(NHCH 2 ),37.2(COCH 2 ),34.6-14.8(CH 3 CO,CH 2 ,CH 2 CH 3 )。HRMS(ESI)calcd for [C 45 H 73 O 10 N 3 Na] +838.5188;found 838.5181.

[0182] [Example 31. Synthesis of compound 31]

[0183] Compound 31 was obtained by treating a solution of 30 in MeOH (10 mL) with 1 M NaOMe in MeOH (155 μL), followed by neutralization with Amberlite® IR120 hydrogen foam, filtration, evaporation and lyophilization. Column chromatography 2:1 EtOAc-cyclohexane. Yield: 130 mg (quantitative). R f 0.40 (2:1 EtOAc-cyclohexane). [α] D +21.90 (during c1.0 DCM). 1 H NMR (500 MHz, CDCl 3 ):δ=7.34-7.16(m,5H,CH-arom),4.98d,1H,J 1,2 =3.7Hz,H-1),4.78(dd,1H, 2 J H,H =11.0Hz,OCH 2 Ph), 4.48(dd, 1H, J 3,4 =7.0Hz,J 4,5 =5.9Hz,H-4),4.45(t,1H,J 6a,6b =J 5,6a =8.8Hz,H-6aH-6a),4.13(dd,1H,J 5,6b =6.1Hz,H-6b),3.66(m,1H,H-5),3.60(m,2H,OCH 2 CH),3.51(dd,1H,J 2,3 =9.3Hz,H-2),3.47(bt,1H,H-3),3.35(m,1H,OCH 2 CH), 3.10(m, 2H, NHCH 2 ), 2.16(t,2H,COCH 2 ), 1.78-0.79(m,48H,CH 2 ,CH 2 CH 3 ). 13 C NMR (125.7MHz, CDCl 3): δ = 174.8, 170.4, 157.1 (CO carbamate), 138.6-127.3 (C-arom), 82.5 (C-1), 81.7 (C-3), 75.4 (OCH 2 CH),74.1(C-2),71.7(C-5),67.7(C-6),67.2(C-4),53.5(OCH 2 CH), 52.7(CH 2 Ph), 39.4(NHCH 2 ), 35.6(COCH 2 ), 33.4-13.3(CH 3 CO,CH 2 ,CH 2 CH 3 ).HRMS(ESI)calcd for [C 41 H 69 O 8 N 3 Na] + 754.4977;found 754.4970.

[0184] Example 32. Stability of glycolipid mimetics of the present invention against the action of glucosidases. Representative compounds 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 23, 25, 27, and 29 were examined for their glycosidic bond stability when incubated with human fibroblast lysate for 4 h. For this purpose, cells (10 6 cells mL -1 ) and place in ice-cold H 2The cells were placed in 0 and dissolved by sonication. Insoluble material was removed by centrifugation at 15,000 rpm for 5 min, and protein concentration was measured using a Protein Assay Rapid Kit (WAKO, Tokyo, Japan). 10 μL of the lysate dissolved in 0.1% Triton X-100 in distilled water was incubated at 37 °C with 20 μL of compound solution (200 μM) in 0.1 M citrate buffer, pH 4.5. As a control, the activity of several lysosomal glycosidases was confirmed using fluorescent substrates. The substrates were 4-methylumbelliferone (4-MU)-linked β-D-glucopyranoside (for GCase), α-D-glucopyranoside (for α-glucosidase), α-D-galactopyranoside (for α-galase), and β-D-galactopyranoside (for β-galactosidase). The liberated 4-methylumbelliferone was measured in blackwell plates using a Perkin Elmer Luminescence Spectrometer (excitation wavelength: 340 nm, emission wavelength: 460 nm).No traces of free polysubstituted 2-oxa-3-oxoindolizines that could result from hydrolysis of the glycolipid mimics were detected by gas chromatography upon trimethylsilylation, thus confirming the stability of the compounds against the action of glycosidases. [Example 33. Suppression of LPS-induced inflammation (in vitro spleen cells)]

[0185] Spleen cells were treated simultaneously with the compounds of the present invention and LPS to evaluate the inhibitory function of the compounds against LPS-induced inflammation. Selected results are shown in Figure 1. Some compounds, especially compounds 8, 10, 12, 14, 18, and 20 in Table 1, showed significant inhibitory function against inflammation.

[0186] [Example 34. Suppression of LPS-induced inflammation (BMDM in vitro)]

[0187] Because macrophages are the primary responders to LPS-induced inflammation, selected compounds were evaluated for their ability to suppress LPS-induced inflammation in bone marrow-derived macrophages (BMDMs). The data shown in Figure 2 indicate that compound 12 is particularly efficient at suppressing LPS-induced inflammation.

[0188] [Example 35. Suppression of LPS-induced inflammation in vivo]

[0189] To investigate the anti-inflammatory function in vivo, we evaluated the ability of compound 12 to suppress LPS-induced inflammation in B6 mice. In Figure 3, the levels of IL-6 and TNFα in serum were shown to be significantly suppressed when injected twice within 30 min after LPS treatment, confirming that compound 12 efficiently suppresses LPS-induced inflammation.

[0190] [Example 36. ERK and p38 of the MAPK family, as well as STAT3, are inhibited by novel compounds]

[0191] Using multiplex bead arrays, we investigated the inhibitory effects of the novel compounds on signal transduction. As a representative example, in Figure 4, phosphorylation of the MAPK family ERK and p38 was significantly decreased by compound 12, but not JNK, compared to LPS treatment alone. Therefore, the novel compounds are considered to exert their anti-inflammatory function by inhibiting the phosphorylation of ERK and p38. In addition, phosphorylation of STAT3 was significantly decreased.

[0192] [Example 37. Suppression of αGalCer-induced inflammation (in vitro spleen cells)]

[0193] Spleen cells were treated simultaneously with the compounds of the present invention and αGalCer to evaluate their ability to suppress αGalCer-induced inflammation. Selected results are shown in Figure 5. Some compounds, especially compounds 2, 6 and 12 in Table 1, showed significant anti-inflammatory function.

[0194] [Example 38. Immunostimulatory function of compounds (in vitro spleen cells)]

[0195] The immune stimulatory function of the compounds was evaluated by treating spleen cells with only the compounds of the present invention and measuring their ability to promote secretion of IFN-γ and IL-4. As a representative example, in FIG. 6, compounds 12, 18, 22, 27, and 29 were effective in promoting the production of IFNγ but did not promote the production of IL-4, supporting the fact that compounds 12, 18, 22, 27, and 29 are Th1 biased. Conversely, as another representative example, compound 8 was also excellent at inducing IL-4 secretion but did not induce IFNγ, supporting the fact that compound 8 is Th2 biased.

[0196] [Example 39. Suppression of OVA-induced airway hyperresponsiveness (AHR) and inflammation in vivo]

[0197] Using a Th2 OVA-induced AHR mouse model, we evaluated the Th2 inflammation suppression ability of selected compounds 8, 12, 18 and 27. The results showed that compounds 8, 12 and 18 could suppress the development of AHR (Figure 7). Furthermore, we observed that compound 12 could significantly suppress the increase of IL-13 and IL-4, which are major inducers of AHR, in BALF (Figure 8) and lungs (protein in Figure 9 and mRNA in Figure 10).

[0198] [Example 40. Evaluation of the adjuvant function of compounds in vivo]

[0199] In addition to evaluating the ability of novel compounds to suppress inflammation, we also investigated their ability to act as adjuvants, i.e., promote desirable immunological trends in vaccine development. Selected compounds 8, 12, 18, 27, and 29 were measured for their in vivo adjuvant ability to induce IFNγ and IL-4 in B6 mice (Figure 11). Compounds 8, 12, 27, and 29 significantly demonstrated the ability to induce both IFNγ and IL-4 2 hours after injection, with significant detectable levels of both cytokines even at 18 hours after injection. Compound 18 only demonstrated significant serum IFNγ levels at both time points. This result strongly supports the use of the compounds of the present invention as adjuvants in vaccine formulations.

[0200] [Example 41. Compound 12 promotes DC maturation in vivo]

[0201] The ability of selected compounds 8, 12, 18, 27 and 29 in promoting DC maturation in vivo was evaluated by measuring the mRNA level of DC maturation marker CD86 in the spleen of mice injected with the compounds of the present invention.It was shown that compound 12 is injected into mice and induces a significant increase in CD86 mRNA expression in the spleen of mice (Figure 12).This result strongly supports the use of compound 12 in vaccine formulations, since DC maturation is essential for the development of a robust immune response.

[0202] [Example 42. Compound 12 promotes Th1 immune responses in vivo]

[0203] Compounds 12 and 27 were injected into OT-1 mice (transgenic mice expressing TCR specific for ovalbumin OVA peptide) to verify their Th1-biased immunomodulatory properties. In Figure 13, compound 12 significantly increased CD8 + It was observed to induce T cell proliferation, indicating that compound 12 can promote a Th1 immune response.

[0204] [Example 43. Adjuvant effect of compound 12 is MyD88-dependent and Th1-biased]

[0205] To determine whether the adjuvant function of representative compound 12 is MyD88-dependent, experiments were performed using immune cells isolated from MyD88 knockout (KO) mice. As a result, the ability of compound 12 to induce IFNγ was completely abolished in spleen cells isolated from MyD88 knockout mice (Figure 14). This result also confirmed the Th1-biased nature of compound 12, as no IL-4 induction was observed. Next, the ability of bone marrow-derived dendritic cells (BMDCs) from MyD88 KO mice to produce IL-12p40 in response to compound 12 was found to be significantly suppressed compared to BMDCs from wild-type mice (Figure 15). The data was dose-dependent, with the difference becoming more pronounced at higher concentrations. Finally, compound 12 treatment-induced BMDC maturation was found to be inhibited in BMDCs from MyD88-deficient mice (Figure 16). Taken together, these results support that the adjuvant function of compound 12 is MyD88-dependent. [Brief description of the drawings]

[0206] [Figure 1] Inhibition of LPS-induced inflammation (in vitro spleen cells) Spleen cells were treated simultaneously with the compound of the present invention and LPS to evaluate the inhibitory function of the compound against LPS-induced inflammation, and some compounds showed significant inhibitory function. [Diagram 2] Compounds 12 and 27 were evaluated for their ability to suppress LPS-induced inflammation in bone marrow derived macrophages (BMDM in vitro), and both showed significant suppression of IL-6 and TNFα. [Diagram 3] Figure 1 shows the suppression of LPS-induced inflammation in vivo. The in vivo ability of compound 12 in suppressing LPS-induced inflammation in B6 mice was evaluated as shown in the scheme. Compound 12 was shown to significantly suppress LPS-induced serum IL-6 and TNFα when injected twice at 30 minutes after LPS treatment. [Figure 4] We show that the MAPK family ERK and p38, as well as STAT3, are inhibited by the novel compound. Using a multiplex bead array, we investigated how the novel compound exerts its inhibitory effect from the perspective of signal transduction, using compound 12, a representative compound of the present invention. Phosphorylation of the mitogen-activated protein kinases (MAPKs), ERK and p38, was significantly decreased by compound 12, but phosphorylation of JNK was not decreased. A significant decrease in phosphorylation of STAT3 was also observed. [Diagram 5] Inhibition of αGalCer-induced inflammation (in vitro spleen cells) Spleen cells were treated simultaneously with the compound of the present invention and αGalCer to evaluate the inhibitory function of the compound against αGalCer-induced inflammation, and some compounds showed significant inhibitory function. [Figure 6] Show the immune stimulating function of compound (in vitro spleen cells).Spleen cells are treated with the compound of the present invention alone to evaluate the immune stimulating function of compound.Compounds 12, 18, 22, 27 and 29 induce significant IFNγ secretion, and compound 8 induces significant IL-4 secretion. [Figure 7] Inhibition of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) in vivo. The in vivo Th2 inflammation suppression ability of selected compounds 8, 12, 18 and 27 was evaluated using an OAV-induced AHR mouse model. Compounds 8, 12 and 18 were confirmed to suppress AHR. [Figure 8] Inhibition of OVA-induced airway inflammation in vivo (BALF). Bronchoalveolar lavage fluid (BALF) from mice in OAV-induced AHR experiments was examined for IL-13 and IL-4 levels. Compound 12 significantly inhibited both IL-13 and IL-4 levels. Compound 27 showed significant inhibition only for IL-13, and compound 18 showed significant inhibition only for IL-4. [Figure 9]Inhibition of OVA-induced airway inflammation in vivo (lung protein). IL-13 and IL-4 protein levels were examined in the lungs of mice in the OAV-induced AHR experiment. Compound 12 significantly inhibited the levels of IL-13 and IL-4. Compounds 8, 18, and 27 showed significant inhibition only for IL-13. [Figure 10] Inhibition of OVA-induced airway inflammation in vivo (lung mRNA). IL-13 and IL-4 mRNA levels were examined from the lungs of mice subjected to OAV-induced AHR experiments. Compound 12 significantly inhibited IL-13 mRNA levels. [Figure 11] The adjuvant function of the compounds in vivo is shown. The adjuvant function of selected compounds 8, 12, 18, 27, and 29 in vivo was evaluated by measuring the serum levels of IFNγ and IL-4 induced after injection in B6 mice. Compounds 8, 12, 27, and 29 showed significant ability to induce both IFNγ and IL-4 2 hours after injection, and showed significant detectable levels of both cytokines even 18 hours after injection. Compound 18 only showed significant serum IFNγ levels at any time point. [Figure 12] This shows that compound 12 promotes the maturation of dendritic cell (DC) in vivo. The ability of selected compounds 8, 12, 18, 27 and 29 to promote DC maturation in vivo is evaluated by the mRNA level of DC maturation marker CD86 in the spleen of mice injected with the compounds of the present invention. It is observed that compound 12 induces a significant increase in the mRNA of CD86. [Figure 13] Compound 12 promotes Th1 immune response in vivo. The adjuvant potential of selected compounds 12 and 27 in vivo was evaluated by their ability to promote CD8+ T cell proliferation in the spleen of OT-1 adoptive transfer mouse model, as shown in the scheme. Compound 12 was observed to induce significant CD8+ T cell proliferation, indicating that compound 12 can promote Th1 immune response. [Figure 14]The adjuvant of compound 12 is shown to be myeloid differentiation primary response 88 (MyD88) dependent and Th1 biased (in vitro spleen cells). The dependency of the biological function of the compounds of the present invention on functional MyD88 was examined using immune cells isolated from MyD88 knockout mice with representative compound 12. As a result, the ability of compound 12 to induce IFNγ in splenocytes isolated from MyD88 knockout mice was completely abolished. IL-4 was not detected with compound 12 treatment, indicating a Th1 biased nature. [Figure 15] We show that the adjuvant activity of compound 12 is MyD88-dependent (bone marrow-derived dendritic cells-BMDCs-in vitro). Continuing our investigation into the dependency of the compounds of the present invention on functional MyD88 for biological function, we found that the ability of bone marrow-derived dendritic cells (BMDCs) from MyD88 KO mice to produce IL-12p40 in response to compound 12 was significantly suppressed compared to BMDCs from wild-type mice. This effect was dose-dependent, and the difference became more pronounced with increasing concentrations. [Figure 16] This shows that promotion of BMDC maturation by compound 12 is MyD88-dependent. Continuing our investigation into the dependency of the compounds of the present invention on functional MyD88 for biological function, we found that the maturation of BMDCs induced by treatment with compound 12 was inhibited in BMDCs from MyD88-deficient mice.

Claims

1. A compound of formula I: 【Chemistry 1】 Where: R 1 are each independently -H, -CH 2 Ph(Bn), -COPh, -CO-C 1 -C 12 Alkyl, C 1 -C 12 alkyl, where R 1 each independently optionally represents one or more groups R 2 is replaced by; R 2 is -OH, -N(R 3 ) 2 , -N 3 , C 1 -C 4 is alkyl or halogen; R 3 are each independently H or C 1 -C 4 is alkyl; X is O, S, NH or CH 2 and Y is a group NH-C(=O)-Y', a group NH-C(=O)-NHY', a group NH-C(=S)-NHY', a group NH-SO 2 -Y' or a group of formula Ia: 【Chemistry 2】 Y′ is one or more groups R 4 C optionally substituted with 1 -C 25 is alkyl; R 4 is -OH, -OCH 2 Ph(-OBn),-OCH 2 Ph(-OBz), C 1 -C 12 Alkyl, —O—C 1 -C 12 Alkyl, -S-C 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 and Cy 1 is a 5- to 14-membered ring which may be saturated, partially unsaturated or aromatic, optionally containing a total of 1 to 4 identical or different heteroatoms selected from N, O, S, or P; Cy 1 is optionally fused to a 5- or 6-membered carbocyclic or heterocyclic ring, which may be saturated, partially unsaturated, or aromatic; Cy 1 is optionally phenyl, halogen, C 1 -C 4 Alkyl, halo-C 1 -C 4 Alkyl, —O—C 1 -C 4 Alkyl, -OCOO-C 1 -C 4 Alkyl, —CO—C 1 -C 4 Alkyl, S-C 1 -C 4 Alkyl or N 3 -C 1 -C 4 substituted with one or more groups selected from alkyl; Z is -CO-OC 4 -C 25 Alkyl, —CO—NH—C 4 -C 25 Alkyl or C 4 -C 25 alkyl, where Z is optionally selected from one or more groups R 5 is replaced by; and R 5 are each independently -OH, -OC(=O)Ph(-OBz), C 1 -C 12 Alkyl, —O—C 1 -C 12 Alkyl, -S-C 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 It is.

2. R 1 are each independently -H, -CH 2 Ph(Bn), -CO-C 1 -C 12 alkyl; R 1 each independently optionally represents one or more groups R 2 2. The compound of formula I according to claim 1, substituted by:

3. 3. A compound of formula I according to claim 1 or 2, wherein X is O or S.

4. Y is a group NH-C(=O)-Y', a group NH-C(=S)-NHY', a group NH-SO 2 A compound of formula I according to any one of claims 1 to 3, which is -Y', or a group of formula Ia.

5. Y is a group NH-C(=O)-Y' or a group NH-C(=S)-NHY', a group NH-SO 2 -Y'; Y′ optionally represents one or more groups R 4 C substituted with 1 -C 25 is alkyl; R 4 is -OH, -OCH 2 Ph(-OBn), C 1 -C 12 Alkyl, —O—C 1 -C 12 Alkyl, -S-C 1 -C 12 Alkyl, -N(R 3 ) 2 , -N 3 , halogen or Cy 1 5. A compound of formula I according to any one of claims 1 to 4, wherein

6. Y is a group of formula Ia; and Y′ optionally represents one or more groups R 4 C substituted with 1 -C 25 5. A compound of formula I according to any one of claims 1 to 4, which is alkyl.

7. Z is -CO-NH-C 8 -C 20 6. A compound of formula I according to any one of claims 1 to 5, which is a straight chain alkyl.

8. Z is C 4 -C 25 alkyl, Z is two groups R 5 is substituted with; and R 5 are each independently -OH or -OC(=O)Ph(-OBz); 7. A compound of formula I according to any one of claims 1 to 4 and 6.

9. 2. A compound of formula I according to claim 1 selected from: 【Table 1】

10. 10. A pharmaceutical composition comprising at least one compound of formula I as defined in any one of claims 1 to 9 or a mixture or combination thereof.

11. 10. A compound of formula I as defined in any one of claims 1 to 9 or a pharmaceutical composition thereof for use as a medicament.

12. A compound of formula I as defined in any one of claims 1 to 9 or a pharmaceutical composition thereof for use in the treatment and / or prevention of immune diseases caused by a Th1 / Th2 imbalance.

13. 13. A compound of formula I according to claim 12 for use in the treatment and / or prevention of a disease selected from metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune-mediated hepatitis, autoimmune diseases, transplant rejection pathologies, atherosclerosis, airway hyperresponsiveness, asthma, allergic rhinitis and neurodegenerative diseases.

14. A vaccine comprising an effective amount of a compound of formula I according to any one of claims 1 to 9 and a vaccinal agent.

15. 15. The vaccine of claim 14, wherein the vaccine agent is selected from killed microorganisms, live attenuated microorganisms, toxoids and fragments of inactivated or attenuated microorganisms, synthetic peptide or glycopeptide constructs, ribonucleic acid (RNA)-based vaccines or deoxyribonucleic acid (DNA)-based vaccines.